

# S Vincent Rajkumar

## List of PR Articles by Year in descending order

Source: [//exaly.com/author-pdf/5201682/publications.pdf](https://exaly.com/author-pdf/5201682/publications.pdf)

Version: 2025-02-01

666

PR articles

63,235

PR citations

680

107

PR h-index

479

243

g-index

816

documents

83060

doc citations

431

127

h-index

35446

citing authors

#	ARTICLE	IF	PR CITATIONS
1	Mode of progression in smoldering multiple myeloma: a study of 406 patients. Blood Cancer Journal, 2024, 14, .	7.9	21
2	Once-weekly versus twice-weekly bortezomib in newly diagnosed multiple myeloma: a real-world analysis. Blood Cancer Journal, 2024, 14, .	7.9	20
3	Outcomes of patients with multiple myeloma refractory to standard dose vs low dose lenalidomide. Blood Cancer Journal, 2024, 14, .	7.9	5
4	Three-dimensional telomere profiling predicts risk of progression in smoldering multiple myeloma. American Journal of Hematology, 2024, 99, 1532-1539.	6.1	7
5	Multiple myeloma: 2024 update on diagnosis, risk stratification, and management. American Journal of Hematology, 2024, 99, 1802-1824.	6.1	285
6	Clinical features associated with poor response and early relapse following BCMA-directed therapies in multiple myeloma. Blood Cancer Journal, 2024, 14, .	7.9	13
7	Progression-free survival as a surrogate endpoint in myeloma clinical trials: an evolving paradigm. Blood Cancer Journal, 2024, 14, .	7.9	12
8	Functional variant rs9344 at 11q13.3 regulates CCND1 expression in multiple myeloma with t(11;14). Leukemia, 2024, 39, 42-50.	10.4	0
9	Risk factors for severe infection and mortality In patients with COVID-19 in patients with multiple myeloma and AL amyloidosis. American Journal of Hematology, 2023, 98, 49-55.	6.1	22
10	Thrombosis in multiple myeloma: Risk estimation by induction regimen and association with overall survival. American Journal of Hematology, 2023, 98, 413-420.	6.1	15
11	A pooled analysis of outcomes according to cytogenetic abnormalities in patients receiving ixazomib-vs placebo-based therapy for multiple myeloma. Blood Cancer Journal, 2023, 13, .	7.9	2
12	Survival trends in young patients with Waldenström macroglobulinemia: Over five decades of experience. American Journal of Hematology, 2023, 98, 432-439.	6.1	8
13	Ixazomib Versus Placebo as Postinduction Maintenance Therapy in Newly Diagnosed Multiple Myeloma Patients: An Analysis by Age and Frailty Status of the TOURMALINE-MM4 Study. Clinical Lymphoma, Myeloma and Leukemia, 2023, 23, 491-504.	1.0	4
14	Artificial intelligence-enabled screening strategy for drug repurposing in monoclonal gammopathy of undetermined significance. Blood Cancer Journal, 2023, 13, .	7.9	3
15	Multiple myeloma with acute light chain cast nephropathy. Blood Cancer Journal, 2023, 13, .	7.9	44
16	A phase 1/2 of carfilzomib and melphalan conditioning for autologous stem cell transplantation for multiple myeloma (CARMEL). American Journal of Hematology, 2023, 98, 1277-1285.	6.1	1
17	Conditional survival in multiple myeloma and impact of prognostic factors over time. Blood Cancer Journal, 2023, 13, .	7.9	19
18	Natural history, predictors of development of extramedullary disease, and treatment outcomes for patients with extramedullary multiple myeloma. American Journal of Hematology, 2023, 98, 1540-1549.	6.1	43

#	ARTICLE	IF	PR CITATIONS
19	Muscle and fat composition in patients with newly diagnosed multiple myeloma. <i>Blood Cancer Journal</i> , 2023, 13, .	7.9	12
20	Kidney Transplantation in Patients With Monoclonal Gammopathy of Renal Significance (MGRS)â€“Associated Lesions: A Case Series. <i>American Journal of Kidney Diseases</i> , 2022, 79, 202-216.	1.4	25
21	Mortality trends in multiple myeloma after the introduction of novel therapies in the United States. <i>Leukemia</i> , 2022, 36, 801-808.	10.4	90
22	Prognostic significance of acquired 1q22 gain in multiple myeloma. <i>American Journal of Hematology</i> , 2022, , .	6.1	8
23	Characteristics and risk factors for thrombosis in <sc>POEMS</sc> syndrome: A retrospective evaluation of 230 patients. <i>American Journal of Hematology</i> , 2022, 97, 209-215.	6.1	10
24	Impact of achieving a complete response to initial therapy of multiple myeloma and predictors of subsequent outcome. <i>American Journal of Hematology</i> , 2022, 97, 267-273.	6.1	12
25	Kidney Transplant Outcomes of Patients With Multiple Myeloma. <i>Kidney International Reports</i> , 2022, 7, 752-762.	2.5	21
26	A simple additive staging system for newly diagnosed multiple myeloma. <i>Blood Cancer Journal</i> , 2022, 12, .	7.9	80
27	Multicentric Castleman disease: A single center experience of treatment with a focus on autologous stem cell transplantation. <i>American Journal of Hematology</i> , 2022, , .	6.1	4
28	Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group. <i>Lancet Haematology</i> ,the, 2022, 9, e143-e161.	9.2	145
29	Utility of PET/CT in assessing early treatment response in patients with newly diagnosed multiple myeloma. <i>Blood Advances</i> , 2022, 6, 2763-2772.	5.1	25
30	Prevalence of heavy chain MGUS by race and family history risk groups using a high-sensitivity screening method. <i>Blood Advances</i> , 2022, 6, 3746-3750.	5.1	7
31	Body mass index associated with monoclonal gammopathy of undetermined significance (MGUS) progression in Olmsted County, Minnesota. <i>Blood Cancer Journal</i> , 2022, 12, .	7.9	30
32	Longitudinal Patient Reported Outcomes with CAR-T Cell Therapy Versus Autologous and Allogeneic Stem Cell Transplant. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 473-482.	2.0	56
33	Single-Cell Proteomics and Tumor RNAseq Identify Novel Pathways Associated With Clofazimine Sensitivity in PI- and IMiD- Resistant Myeloma, and Putative Stem-Like Cells. <i>Frontiers in Oncology</i> , 2022, 12, .	2.7	9
34	Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. <i>American Journal of Hematology</i> , 2022, 97, 1086-1107.	6.1	640
35	The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. <i>Leukemia</i> , 2022, 36, 1720-1748.	10.4	2,949
36	Hypovitaminosis D Is Prevalent in Patients With Renal AL Amyloidosis and Associated With Renal Outcome. <i>Frontiers in Endocrinology</i> , 2022, 13, .	4.1	1

#	ARTICLE	IF	PR CITATIONS
37	Does a Multiple Myeloma Polygenic Risk Score Predict Overall Survival of Patients with Myeloma?. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 1863-1866.	1.2	3
38	Smoldering multiple myeloma current treatment algorithms. Blood Cancer Journal, 2022, 12, .	7.9	58
39	Second- and third-line treatment strategies in multiple myeloma: a referral-center experience. Blood Cancer Journal, 2022, 12, .	7.9	8
40	Monoclonal Gammopathy of Undetermined Significance. Annals of Internal Medicine, 2022, 175, ITC177-ITC192.	10.4	31
41	Characterization and prognostic implication of delayed complete response in AL amyloidosis. European Journal of Haematology, 2021, 106, 354-361.	1.9	6
42	Use of beta blockers is associated with survival outcome of multiple myeloma patients treated with pomalidomide. European Journal of Haematology, 2021, 106, 433-436.	1.9	6
43	Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study. Lancet Oncology, The, 2021, 22, 142-154.	26.0	61
44	Outcomes with different administration schedules of bortezomib in bortezomib, lenalidomide and dexamethasone (<scp>VRd</scp>) as firstâ€line therapy in multiple myeloma. American Journal of Hematology, 2021, 96, 330-337.	6.1	21
45	Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial. Lancet Haematology,the, 2021, 8, e45-e54.	9.2	115
46	Disease monitoring with quantitative serum IgA levels provides a more reliable response assessment in multiple myeloma patients. Leukemia, 2021, 35, 1428-1437.	10.4	13
47	Prognosis of young patients with monoclonal gammopathy of undetermined significance (MGUS). Blood Cancer Journal, 2021, 11, .	7.9	22
48	Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report. Blood Cancer Journal, 2021, 11, .	7.9	146
49	Prognostic restaging after treatment initiation in patients with AL amyloidosis. Blood Advances, 2021, 5, 1029-1036.	5.1	14
50	Coagulation Abnormalities in Light Chain Amyloidosis. Mayo Clinic Proceedings, 2021, 96, 377-387.	3.1	19
51	Safety and Efficacy of Daratumumab in Patients with Proliferative GN with Monoclonal Immunoglobulin Deposits. Journal of the American Society of Nephrology: JASN, 2021, 32, 1163-1173.	0.4	68
52	Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma. Blood, 2021, 137, 3616-3628.	4.2	88
53	Clinical Characteristics and Outcomes of Patients With Primary Plasma Cell Leukemia in the Era of Novel Agent Therapy. Mayo Clinic Proceedings, 2021, 96, 677-687.	3.1	35
54	MASS-FIX for the detection of monoclonal proteins and light chain N-glycosylation in routine clinical practice: a cross-sectional study of 6315 patients. Blood Cancer Journal, 2021, 11, .	7.9	40

#	ARTICLE	IF	PR CITATIONS
55	Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. <i>Lancet Oncology</i> , The, 2021, 22, e105-e118.	26.0	222
56	Use of endpoints in multiple myeloma randomized controlled trials over the last 15 years: A systematic review. <i>American Journal of Hematology</i> , 2021, 96, 690-697.	6.1	22
57	Assessment of fixed-duration therapies for treatment-naïve Waldenström macroglobulinemia. <i>American Journal of Hematology</i> , 2021, 96, 945-953.	6.1	24
58	Treatment of AL Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement 2020 Update. <i>Mayo Clinic Proceedings</i> , 2021, 96, 1546-1577.	3.1	66
59	Sequencing of myeloma therapy: Finding the right path among many standards. <i>Hematological Oncology</i> , 2021, 39, 68-72.	2.2	10
60	Serum BCMA levels predict outcomes in MGUS and smoldering myeloma patients. <i>Blood Cancer Journal</i> , 2021, 11, .	7.9	41
61	The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma: A Cross-analysis of a Population-based Registry and a Tertiary Care Center. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 451-460.e2.	1.0	16
62	Second Stem Cell Transplantation for Relapsed Refractory Light Chain (AL) Amyloidosis. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 589.e1-589.e6.	2.0	5
63	Prognostic impact of posttransplant FDG PET/CT scan in multiple myeloma. <i>Blood Advances</i> , 2021, 5, 2753-2759.	5.1	18
64	Treatment and outcome of newly diagnosed multiple myeloma patients > 75 years old: a retrospective analysis. <i>Leukemia and Lymphoma</i> , 2021, 62, 3011-3018.	1.5	3
65	Venetoclax for the treatment of multiple myeloma: Outcomes outside of clinical trials. <i>American Journal of Hematology</i> , 2021, 96, 1131-1136.	6.1	30
66	The Prognostic Role of MYC Structural Variants Identified by NGS and FISH in Multiple Myeloma. <i>Clinical Cancer Research</i> , 2021, 27, 5430-5439.	6.9	30
67	Disease outcomes and biomarkers of progression in smoldering Waldenström macroglobulinaemia. <i>British Journal of Haematology</i> , 2021, 195, 210-216.	2.4	26
68	The Effect of Duration of Lenalidomide Maintenance and Outcomes of Different Salvage Regimens in Patients with Multiple Myeloma (MM). <i>Blood Cancer Journal</i> , 2021, 11, .	7.9	16
69	Comparison of the current renal staging, progression and response criteria to predict renal survival in AL amyloidosis using a Mayo cohort. <i>American Journal of Hematology</i> , 2021, 96, 446-454.	6.1	12
70	Assessing the prognostic utility of smoldering multiple myeloma risk stratification scores applied serially post diagnosis. <i>Blood Cancer Journal</i> , 2021, 11, .	7.9	23
71	Family history of plasma cell disorders is associated with improved survival in MGUS, multiple myeloma, and systemic AL amyloidosis. <i>Leukemia</i> , 2021, 36, 1058-1065.	10.4	7
72	Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage. <i>Blood Cancer Journal</i> , 2021, 11, .	7.9	150

#	ARTICLE	IF	PR CITATIONS
73	“Real-life” data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma—the Mayo Clinic experience. <i>Blood Cancer Journal</i> , 2021, 11, .	7.9	44
74	Survival impact of achieving minimal residual negativity by multi-parametric flow cytometry in AL amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2020, 27, 13-16.	4.7	30
75	Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2020, 38, 1126-1137.	21.6	245
76	Community-Based Study of Celiac Disease Autoimmunity Progression in Adults. <i>Gastroenterology</i> , 2020, 158, 151-159.e3.	1.0	26
77	Hematopoietic score predicts outcomes in newly diagnosed multiple myeloma patients. <i>American Journal of Hematology</i> , 2020, 95, 4-9.	6.1	18
78	Cytogenetic Features and Clinical Outcomes of Patients With Non-secretory Multiple Myeloma in the Era of Novel Agent Induction Therapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 53-56.	1.0	12
79	Venous thromboembolism risk with contemporary lenalidomide-based regimens despite thromboprophylaxis in multiple myeloma: A systematic review and meta-analysis. <i>Cancer</i> , 2020, 126, 1640-1650.	4.1	42
80	Enhancing the R-ISS classification of newly diagnosed multiple myeloma by quantifying circulating clonal plasma cells. <i>American Journal of Hematology</i> , 2020, 95, 310-315.	6.1	55
81	Impact of MYD88 <sup>L265P</sup> mutation status on histological transformation of Waldenström Macroglobulinemia. <i>American Journal of Hematology</i> , 2020, 95, 274-281.	6.1	49
82	Use of Bone-Modifying Agents Among Medicare Beneficiaries With Multiple Myeloma. <i>JAMA Oncology</i> , 2020, 6, 296.	14.6	14
83	Multiple myeloma current treatment algorithms. <i>Blood Cancer Journal</i> , 2020, 10, .	7.9	298
84	Implications of MYC Rearrangements in Newly Diagnosed Multiple Myeloma. <i>Clinical Cancer Research</i> , 2020, 26, 6581-6588.	6.9	51
85	International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM). <i>Blood Cancer Journal</i> , 2020, 10, .	7.9	239
86	Predictors of short-term survival in Waldenström Macroglobulinemia. <i>Leukemia and Lymphoma</i> , 2020, 61, 2975-2979.	1.5	5
87	Refining amyloid complete hematological response: Quantitative serum free light chains superior to ratio. <i>American Journal of Hematology</i> , 2020, 95, 1280-1287.	6.1	23
88	Treatments for newly diagnosed multiple myeloma: when endurance is interrupted “ Authors' reply. <i>Lancet Oncology</i> , The, 2020, 21, e541.	26.0	0
89	Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities. <i>Blood Advances</i> , 2020, 4, 3509-3519.	5.1	90
90	Clinical Trial End Points in Severe COVID-19. <i>Mayo Clinic Proceedings</i> , 2020, 95, 1578-1580.	3.1	2

#	ARTICLE	IF	PR CITATIONS
91	In vitro and ex vivo gene expression profiling reveals differential kinetic response of HSPs and UPR genes is associated with PI resistance in multiple myeloma. <i>Blood Cancer Journal</i> , 2020, 10, .	7.9	13
92	Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response. <i>Blood Cancer Journal</i> , 2020, 10, .	7.9	104
93	Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial. <i>Lancet Oncology</i> , The, 2020, 21, 1317-1330.	26.0	223
94	Characteristics of exceptional responders to autologous stem cell transplantation in multiple myeloma. <i>Blood Cancer Journal</i> , 2020, 10, .	7.9	22
95	Correlation between urine ACR and 24-h proteinuria in a real-world cohort of systemic AL amyloidosis patients. <i>Blood Cancer Journal</i> , 2020, 10, .	7.9	17
96	The role of bone marrow biopsy in patients with plasma cell disorders: should all patients with a monoclonal protein be biopsied?. <i>Blood Cancer Journal</i> , 2020, 10, .	7.9	15
97	BiTEing the Tumor. <i>Journal of Clinical Oncology</i> , 2020, 38, 2077-2079.	21.6	8
98	Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT). <i>Blood Cancer Journal</i> , 2020, 10, .	7.9	203
99	Outcomes with early vs. deferred stem cell transplantation in light chain amyloidosis. <i>Bone Marrow Transplantation</i> , 2020, 55, 1297-1304.	3.3	9
100	câ€MYC expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomideâ€dexamethasone in myeloma. <i>European Journal of Haematology</i> , 2020, 105, 35-46.	1.9	9
101	Multiple myeloma: 2020 update on diagnosis, riskâ€stratification and management. <i>American Journal of Hematology</i> , 2020, 95, 548-567.	6.1	693
102	Utilizing multiparametric flow cytometry in the diagnosis of patients with primary plasma cell leukemia. <i>American Journal of Hematology</i> , 2020, 95, 637-642.	6.1	17
103	Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma. <i>Annals of Hematology</i> , 2020, 99, 1793-1804.	1.5	6
104	Coinherited genetics of multiple myeloma and its precursor, monoclonal gammopathy of undetermined significance. <i>Blood Advances</i> , 2020, 4, 2789-2797.	5.1	23
105	Blood mass spectrometry detects residual disease better than standard techniques in light-chain amyloidosis. <i>Blood Cancer Journal</i> , 2020, 10, .	7.9	35
106	Long-term outcomes of IMiD-based trials in patients with immunoglobulin light-chain amyloidosis: a pooled analysis. <i>Blood Cancer Journal</i> , 2020, 10, .	7.9	21
107	Impact of minimal residual negativity using next generation flow cytometry on outcomes in light chain amyloidosis. <i>American Journal of Hematology</i> , 2020, 95, 497-502.	6.1	47
108	Increased Bone Marrow Plasma-Cell Percentage Predicts Outcomes in Newly Diagnosed Multiple Myeloma Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 596-601.	1.0	28

#	ARTICLE	IF	PR CITATIONS
109	Deepening responses associated with improved progression-free survival with ixazomib versus placebo as posttransplant maintenance in multiple myeloma. <i>Leukemia</i> , 2020, 34, 3019-3027.	10.4	18
110	The Case for Masks. <i>Mayo Clinic Proceedings</i> , 2020, 95, 1132-1134.	3.1	1
111	Utility of serum free light chain ratio in response definition in patients with multiple myeloma. <i>Blood Advances</i> , 2020, 4, 322-326.	5.1	8
112	A validated composite organ and hematologic response model for early assessment of treatment outcomes in light chain amyloidosis. <i>Blood Cancer Journal</i> , 2020, 10, .	7.9	34
113	Metaphase cytogenetics and plasma cell proliferation index for risk stratification in newly diagnosed multiple myeloma. <i>Blood Advances</i> , 2020, 4, 2236-2244.	5.1	29
114	The Prognostic Significance of Acquired 1q22 Gain in Multiple Myeloma. <i>Blood</i> , 2020, 136, 9-10.	4.2	0
115	Peripheral blood biomarkers of early immune reconstitution in newly diagnosed multiple myeloma. <i>American Journal of Hematology</i> , 2019, 94, 306-311.	6.1	20
116	Association of elevated serumfree light chains with chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis. <i>Blood Cancer Journal</i> , 2019, 9, .	7.9	12
117	Ten-year survivors in AL amyloidosis: characteristics and treatment pattern. <i>British Journal of Haematology</i> , 2019, 187, 588-594.	2.4	56
118	Depth of organ response in AL amyloidosis is associated with improved survival: new proposed organ response criteria. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2019, 26, 101-102.	4.7	13
119	Comparison of different techniques to identify cardiac involvement in immunoglobulin light chain (AL) amyloidosis. <i>Blood Advances</i> , 2019, 3, 1226-1229.	5.1	8
120	Characteristics of long-term survivors with multiple myeloma: A National Cancer Data Base analysis. <i>Cancer</i> , 2019, 125, 3574-3581.	4.1	10
121	Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. <i>Lancet</i> , 2019, 394, 2096-2107.	52.8	569
122	Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance. <i>Leukemia</i> , 2019, 33, 1736-1746.	10.4	47
123	Tetraploidy is associated with poor prognosis at diagnosis in multiple myeloma. <i>American Journal of Hematology</i> , 2019, 94, .	6.1	22
124	Smoldering Multiple Myeloma. <i>Cancer Journal (Sudbury, Mass )</i> , 2019, 25, 65-71.	1.8	18
125	International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. <i>Lancet Oncology</i> , 2019, 20, e302-e312.	26.0	426
126	Multiple myeloma: Every year a new standard?. <i>Hematological Oncology</i> , 2019, 37, 62-65.	2.2	216

#	ARTICLE	IF	PR CITATIONS
127	Polyclonal serum free light chain elevation is associated with increased risk of monoclonal gammopathies. <i>Blood Cancer Journal</i> , 2019, 9, .	7.9	15
128	Development of thrombocytopenia during first-line treatment and survival outcomes in newly diagnosed multiple myeloma. <i>Leukemia and Lymphoma</i> , 2019, 60, 2960-2967.	1.5	8
129	Clinical features, laboratory characteristics and outcomes of patients with renal <i>versus</i> cardiac light chain amyloidosis. <i>British Journal of Haematology</i> , 2019, 185, 701-707.	2.4	18
130	Histone deacetylase inhibition in combination with MEK or BCL-2 inhibition in multiple myeloma. <i>Haematologica</i> , 2019, 104, 2061-2074.	4.1	29
131	Natural history of multiple myeloma with de novo del(17p). <i>Blood Cancer Journal</i> , 2019, 9, .	7.9	54
132	Two types of amyloidosis presenting in a single patient: a case series. <i>Blood Cancer Journal</i> , 2019, 9, .	7.9	70
133	Prognostic value of minimal residual disease and polyclonal plasma cells in myeloma patients achieving a complete response to therapy. <i>American Journal of Hematology</i> , 2019, 94, 751-756.	6.1	19
134	Incidence of AL Amyloidosis in Olmsted County, Minnesota, 1990 through 2015. <i>Mayo Clinic Proceedings</i> , 2019, 94, 465-471.	3.1	132
135	Substratification of patients with newly diagnosed standardâ€risk multiple myeloma. <i>British Journal of Haematology</i> , 2019, 185, 254-260.	2.4	14
136	Maintenance Therapy with the Oral Proteasome Inhibitor (PI) Ixazomib Significantly Prolongs Progression-Free Survival (PFS) Following Autologous Stem Cell Transplantation (ASCT) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Phase 3 Tourmaline-MM3 Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S19-S20.	1.6	4
137	Prognostic restaging at the time of second-line therapy in patients with AL amyloidosis. <i>Leukemia</i> , 2019, 33, 1268-1272.	10.4	10
138	The role of cement augmentation with percutaneous vertebroplasty and balloon kyphoplasty for the treatment of vertebral compression fractures in multiple myeloma: a consensus statement from the International Myeloma Working Group (IMWG). <i>Blood Cancer Journal</i> , 2019, 9, .	7.9	93
139	Monoclonal gammopathy plus positive amyloid biopsy does not always equal AL amyloidosis. <i>American Journal of Hematology</i> , 2019, 94, .	6.1	21
140	Impact of prior diagnosis of monoclonal gammopathy on outcomes in newly diagnosed multiple myeloma. <i>Leukemia</i> , 2019, 33, 1273-1277.	10.4	21
141	A Modern Primer on Light Chain Amyloidosis in 592 Patients With Mass Spectrometryâ€Verified Typing. <i>Mayo Clinic Proceedings</i> , 2019, , .	3.1	71
142	Impact of acquired del(17p) in multiple myeloma. <i>Blood Advances</i> , 2019, 3, 1930-1938.	5.1	53
143	Outcomes with early response to first-line treatment in patients with newly diagnosed multiple myeloma. <i>Blood Advances</i> , 2019, 3, 744-750.	5.1	32
144	Mate pair sequencing outperforms fluorescence in situ hybridization in the genomic characterization of multiple myeloma. <i>Blood Cancer Journal</i> , 2019, 9, .	7.9	33

#	ARTICLE	IF	PR CITATIONS
145	Detection and prevalence of monoclonal gammopathy of undetermined significance: a study utilizing mass spectrometry-based monoclonal immunoglobulin rapid accurate mass measurement. Blood Cancer Journal, 2019, 9, .	7.9	86
146	Pros and cons of frontline autologous transplant in multiple myeloma: the debate over timing. Blood, 2019, 133, 652-659.	4.2	47
147	Rapid assessment of hyperdiploidy in plasma cell disorders using a novel multi-parametric flow cytometry method. American Journal of Hematology, 2019, 94, 424-430.	6.1	14
148	Molecular signatures of multiple myeloma progression through single cell RNA-Seq. Blood Cancer Journal, 2019, 9, .	7.9	87
149	Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet, The, 2019, 393, 253-264.	52.8	219
150	IgM AL amyloidosis: delineating disease biology and outcomes with clinical, genomic and bone marrow morphological features. Leukemia, 2019, 34, 1373-1382.	10.4	49
151	Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosis. Leukemia, 2019, 34, 1135-1143.	10.4	37
152	Prognostic significance of circulating plasma cells by multi-parametric flow cytometry in light chain amyloidosis. Leukemia, 2018, 32, 1421-1426.	10.4	12
153	Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria. Leukemia, 2018, 32, 2240-2249.	10.4	101
154	Fifty-Year Incidence of Waldenström Macroglobulinemia in Olmsted County, Minnesota, From 1961 Through 2010: A Population-Based Study With Complete Case Capture and Hematopathologic Review. Mayo Clinic Proceedings, 2018, 93, 739-746.	3.1	37
155	The multiple myelomas " current concepts in cytogenetic classification and therapy. Nature Reviews Clinical Oncology, 2018, 15, 409-421.	75.5	270
156	Time to plateau as a predictor of survival in newly diagnosed multiple myeloma. American Journal of Hematology, 2018, 93, 889-894.	6.1	16
157	Analysis of Clinical Factors and Outcomes Associated with Nonuse of Collected Peripheral Blood Stem Cells for Autologous Stem Cell Transplants in Transplant-Eligible Patients with Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2018, 24, 2127-2132.	1.6	23
158	Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia. Annals of Hematology, 2018, 97, 1417-1425.	1.5	87
159	Prognostic significance of interphase FISH in monoclonal gammopathy of undetermined significance. Leukemia, 2018, 32, 1811-1815.	10.4	33
160	The importance of bone marrow examination in patients with light chain amyloidosis achieving a complete response. Leukemia, 2018, 32, 1243-1246.	10.4	13
161	Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance. New England Journal of Medicine, 2018, 378, 241-249.	43.7	569
162	Reply to Castillo et al.. American Journal of Hematology, 2018, 93, .	6.1	3



#	ARTICLE	IF	PR CITATIONS
181	Disease and outcome disparities in multiple myeloma: exploring the role of race/ethnicity in the Cooperative Group clinical trials. <i>Blood Cancer Journal</i> , 2018, 8, .	7.9	80
182	Serum free light chain measurements to reduce 24-hour urine monitoring in patients with multiple myeloma with measurable urine monoclonal protein. <i>American Journal of Hematology</i> , 2018, 93, 1207-1210.	6.1	7
183	Independent Prognostic Value of Stroke Volume Index in Patients With Immunoglobulin Light Chain Amyloidosis. <i>Circulation: Cardiovascular Imaging</i> , 2018, 11, .	3.3	71
184	Predictors of symptomatic hyperviscosity in Waldenström macroglobulinemia. <i>American Journal of Hematology</i> , 2018, 93, 1384-1393.	6.1	38
185	Multiple myeloma: 2018 update on diagnosis, risk stratification, and management. <i>American Journal of Hematology</i> , 2018, 93, 1091-1110.	6.1	189
186	Kidney Involvement of Patients with Waldenström Macroglobulinemia and Other IgM-Producing B Cell Lymphoproliferative Disorders. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 1037-1046.	4.4	65
187	Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. <i>Blood Cancer Journal</i> , 2018, 8, .	7.9	248
188	Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement. <i>Bone Marrow Transplantation</i> , 2018, 54, 353-367.	3.3	103
189	Risk of MGUS in relatives of multiple myeloma cases by clinical and tumor characteristics. <i>Leukemia</i> , 2018, 33, 499-507.	10.4	13
190	Primary systemic amyloidosis in patients with Waldenström macroglobulinemia. <i>Leukemia</i> , 2018, 33, 790-794.	10.4	34
191	Relapse after complete response in newly diagnosed multiple myeloma: implications of duration of response and patterns of relapse. <i>Leukemia</i> , 2018, 33, 730-738.	10.4	27
192	Optimizing deep response assessment for AL amyloidosis using involved free light chain level at end of therapy: failure of the serum free light chain ratio. <i>Leukemia</i> , 2018, 33, 527-531.	10.4	45
193	Novel pedigree analysis implicates DNA repair and chromatin remodeling in multiple myeloma risk. <i>PLoS Genetics</i> , 2018, 14, e1007111.	3.3	41
194	Aurora kinase and FGFR3 inhibition results in significant apoptosis in molecular subgroups of multiple myeloma. <i>Oncotarget</i> , 2018, 9, 34582-34594.	1.7	4
195	Overuse of organ biopsies in immunoglobulin light chain amyloidosis (AL): the consequence of failure of early recognition. <i>Annals of Medicine</i> , 2017, 49, 545-551.	4.1	69
196	Hematology patient reported symptom screen to assess quality of life for AL amyloidosis. <i>American Journal of Hematology</i> , 2017, 92, 435-440.	6.1	21
197	Call for Papers on Clinical Practice Guidelines. <i>Mayo Clinic Proceedings</i> , 2017, 92, 327-328.	3.1	0
198	The prognostic value of multiparametric flow cytometry in AL amyloidosis at diagnosis and at the end of first-line treatment. <i>Blood</i> , 2017, 129, 82-87.	4.2	52

#	ARTICLE	IF	PR CITATIONS
199	Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death. <i>Blood</i> , 2017, 129, 2111-2119.	4.2	298
200	Plasmacytoma of the Temporal Bone, a Great Imitator: Report of Seven Cases and Comprehensive Review of the Literature. <i>Otology and Neurotology</i> , 2017, 38, 400-407.	1.6	14
201	Monoclonal Gammopathy-Associated Peripheral Neuropathy: Diagnosis and Management. <i>Mayo Clinic Proceedings</i> , 2017, 92, 838-850.	3.1	134
202	Outcome of very young (<math>\leq 40</math> years) patients with immunoglobulin light chain (AL) amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2017, 24, 50-51.	4.7	6
203	Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2017, 24, 40-41.	4.7	4
204	Prevalence and predictors of thyroid functional abnormalities in newly diagnosed AL amyloidosis. <i>Journal of Internal Medicine</i> , 2017, 281, 611-619.	7.6	19
205	Impact of concomitant dexamethasone dosing schedule on bortezomib-induced peripheral neuropathy in multiple myeloma. <i>British Journal of Haematology</i> , 2017, 178, 756-763.	2.4	23
206	The prognostic significance of polyclonal bone marrow plasma cells in patients with relapsing multiple myeloma. <i>American Journal of Hematology</i> , 2017, 92, .	6.1	10
207	Clinical presentation and outcomes of patients with type 1 monoclonal cryoglobulinemia. <i>American Journal of Hematology</i> , 2017, 92, 668-673.	6.1	98
208	Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. <i>Lancet Oncology</i> , The, 2017, 18, e206-e217.	26.0	486
209	Therapy for Relapsed Multiple Myeloma. <i>Mayo Clinic Proceedings</i> , 2017, 92, 578-598.	3.1	134
210	Treatment patterns and outcome following initial relapse or refractory disease in patients with systemic light chain amyloidosis. <i>American Journal of Hematology</i> , 2017, 92, 549-554.	6.1	27
211	Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. <i>Lancet</i> , The, 2017, 389, 519-527.	52.8	831
212	Diagnosis and Management of Waldenström Macroglobulinemia. <i>JAMA Oncology</i> , 2017, 3, 1257.	14.6	125
213	Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients. <i>Blood</i> , 2017, 130, 2610-2618.	4.2	109
214	Delineation of the timing of second-line therapy post-autologous stem cell transplant in patients with AL amyloidosis. <i>Blood</i> , 2017, 130, 1578-1584.	4.2	21
215	Elevation of serum lactate dehydrogenase in <math>\leq 40</math> amyloidosis reflects tissue damage and is an adverse prognostic marker in patients not eligible for stem cell transplantation. <i>British Journal of Haematology</i> , 2017, 178, 888-895.	2.4	19
216	Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naïve patients with Waldenström macroglobulinemia. <i>British Journal of Haematology</i> , 2017, 179, 98-105.	2.4	31

#	ARTICLE	IF	PR CITATIONS
217	Efficacy of daratumumab-based therapies in patients with relapsed, refractory multiple myeloma treated outside of clinical trials. <i>American Journal of Hematology</i> , 2017, 92, 1146-1155.	6.1	26
218	Predictors of early treatment failure following initial therapy for systemic immunoglobulin light-chain amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2017, 24, 183-188.	4.7	5
219	Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma. <i>Blood</i> , 2017, 130, 1198-1204.	4.2	61
220	Ixazomib cardiotoxicity: A possible class effect of proteasome inhibitors. <i>American Journal of Hematology</i> , 2017, 92, 220-221.	6.1	30
221	Beta-blockers improve survival outcomes in patients with multiple myeloma: a retrospective evaluation. <i>American Journal of Hematology</i> , 2017, 92, 50-55.	6.1	49
222	Presentation and Outcomes of Localized Immunoglobulin Light Chain Amyloidosis. <i>Mayo Clinic Proceedings</i> , 2017, 92, 908-917.	3.1	90
223	Impact of prior melphalan exposure on stem cell collection in light chain amyloidosis. <i>Bone Marrow Transplantation</i> , 2017, 53, 326-333.	3.3	4
224	Updated Diagnostic Criteria and Staging System for Multiple Myeloma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, , e418-e423.	4.6	270
225	Spectrum of manifestations of monoclonal gammopathy-associated renal lesions. <i>Current Opinion in Nephrology and Hypertension</i> , 2016, 25, 127-137.	2.3	68
226	From the Guest Editor. <i>Cancer Journal (Sudbury, Mass )</i> , 2016, 22, 1-2.	1.8	0
227	Stem cell transplantation compared with melphalan plus dexamethasone in the treatment of immunoglobulin light-chain amyloidosis. <i>Cancer</i> , 2016, 122, 2197-2205.	4.1	40
228	Induction therapy pre-autologous stem cell transplantation in immunoglobulin light chain amyloidosis: a retrospective evaluation. <i>American Journal of Hematology</i> , 2016, 91, 984-988.	6.1	49
229	Increased mortality among men aged 50 years old or above with elevated IgA anti-transglutaminase antibodies: NHANES III. <i>BMC Gastroenterology</i> , 2016, 16, .	2.4	20
230	Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib. <i>Blood</i> , 2016, 128, 2415-2422.	4.2	54
231	Immunoparesis status in immunoglobulin light chain amyloidosis at diagnosis affects response and survival by regimen type. <i>Haematologica</i> , 2016, 101, 1102-1109.	4.1	10
232	The prognostic significance of CD45 expression by clonal bone marrow plasma cells in patients with newly diagnosed multiple myeloma. <i>Leukemia Research</i> , 2016, 44, 32-39.	0.7	30
233	Clinical Features and Treatment Outcomes of Patients With Necrobiotic Xanthogranuloma Associated With Monoclonal Gammopathies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 447-452.	1.0	24
234	Drug Approvals in Oncology: Striking the Right Balance Between Saving Lives and Patient Safety. <i>Mayo Clinic Proceedings</i> , 2016, 91, 689-691.	3.1	1

#	ARTICLE	IF	PR CITATIONS
235	A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 1609-1618.	1.2	24
236	Systemic Immunoglobulin Light Chain Amyloidosisâ€Associated Myopathy: Presentation, Diagnostic Pitfalls, and Outcome. <i>Mayo Clinic Proceedings</i> , 2016, 91, 1354-1361.	3.1	56
237	Long-term outcome of patients with POEMS syndrome: An update of the Mayo Clinic experience. <i>American Journal of Hematology</i> , 2016, 91, 585-589.	6.1	73
238	Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management. <i>American Journal of Hematology</i> , 2016, 91, 719-734.	6.1	409
239	Myeloma today: Disease definitions and treatment advances. <i>American Journal of Hematology</i> , 2016, 91, 90-100.	6.1	152
240	N-terminal fragment of the type-B natriuretic peptide (NT-proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma. <i>American Journal of Hematology</i> , 2016, 91, 1129-1134.	6.1	96
241	International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. <i>Lancet Oncology</i> , The, 2016, 17, e328-e346.	26.0	2,576
242	Treatment of newly diagnosed myeloma: Bortezomib-based triplet. <i>Seminars in Oncology</i> , 2016, 43, 700-702.	1.9	9
243	Impact of Day-100 Response Post Autologous Stem Cell Transplantation (ASCT) in Waldenström Macroglobulinemia (WM). <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S130.	1.6	1
244	Clinical characteristics and outcomes in biclonal gammopathies. <i>American Journal of Hematology</i> , 2016, 91, 473-475.	6.1	35
245	The impact of dialysis on the survival of patients with immunoglobulin light chain (AL) amyloidosis undergoing autologous stem cell transplantation. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 1284-1289.	0.8	29
246	Multiple Myeloma: Diagnosis and Treatment. <i>Mayo Clinic Proceedings</i> , 2016, 91, 101-119.	3.1	494
247	Disease and Outcome Disparities in Multiple Myeloma (MM): Exploring the Role of Race/Ethnicity and Obesity in Cooperative Group Clinical Trials. <i>Blood</i> , 2016, 128, 1192-1192.	4.2	2
248	Predictors of Early Relapse Following Initial Therapy for Systemic Immunoglobulin Light Chain Amyloidosis. <i>Blood</i> , 2016, 128, 2082-2082.	4.2	1
249	Higher c-MYC Expression Is Associated with Ixazomib-Lenalidomide-Dexamethasone (IRd) Progression-Free Survival (PFS) Benefit Versus Placebo-Rd: Biomarker Analysis of the Phase 3 Tourmaline-MM1 Study in Relapsed/Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2016, 128, 243-243.	4.2	3
250	Bendamustine and Rituximab Versus Dexamethasone, Rituximab and Cyclophosphamide in Patients with Waldenstrom Macroglobulinemia (WM). <i>Blood</i> , 2016, 128, 2968-2968.	4.2	4
251	Dexamethasone, Rituximab and Cyclophosphamide (DRC) As Salvage Therapy for Waldenstrom Macroglobulinemia. <i>Blood</i> , 2016, 128, 2972-2972.	4.2	2
252	Clinical Presentation and Outcomes of Patients with Light Chain Amyloidosis Who Have Non-Evaluable Free Light Chains at Diagnosis. <i>Blood</i> , 2016, 128, 3272-3272.	4.2	1

#	ARTICLE	IF	PR CITATIONS
253	Bortezomib Versus Non-Bortezomib Based Treatment for Transplant Ineligible Patients with Light Chain Amyloidosis. <i>Blood</i> , 2016, 128, 3317-3317.	4.2	3
254	Efficacy of Carfilzomib (K), Pomalidomide (P), and Dexamethasone (d) in Heavily Pretreated Patients with Relapsed/ Refractory Multiple Myeloma (RRMM) in a Real World Setting. <i>Blood</i> , 2016, 128, 3337-3337.	4.2	5
255	Practice Patterns of Re-Initiation of Therapy at Time of Relapse or Progression Post- Autologous Stem Cell Transplant (ASCT) Among Patients with AL Amyloidosis. <i>Blood</i> , 2016, 128, 3444-3444.	4.2	1
256	Findings of Whole Body Computed Tomography Compared to Conventional Skeletal Survey in Patients with Monoclonal Plasma Cell Disorders - a Study of the International Myeloma Working Group. <i>Blood</i> , 2016, 128, 4468-4468.	4.2	13
257	Effect of Standard Dose Versus Risk Adapted Melphalan Conditioning on Outcomes in Systemic AL Amyloidosis Patients Undergoing Frontline Autologous Stem Cell Transplant Based on Revised Mayo Stage. <i>Blood</i> , 2016, 128, 4627-4627.	4.2	2
258	Smac mimetic LCL161 overcomes protective ER stress induced by obatoclax, synergistically causing cell death in multiple myeloma. <i>Oncotarget</i> , 2016, 7, 56253-56265.	1.7	23
259	Risk of Monoclonal Gammopathy of Undetermined Significance in First-Degree Relatives of Multiple Myeloma Cases By Cytogenetic Subtype. <i>Blood</i> , 2016, 128, 4425-4425.	4.2	0
260	Clinical Presentation and Outcome of Patients with Myeloid Differentiation Factor 88 Gene (MYD88) Wild-Type Waldenstrom Macroglobulinemia. <i>Blood</i> , 2016, 128, 2960-2960.	4.2	15
261	Prognostic Implications of Multiple Cytogenetic High-Risk Abnormalities in Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2016, 128, 5615-5615.	4.2	0
262	Thyroid Functional Abnormalities in Newly Diagnosed AL Amyloidosis: Frequency and Influence By Type of Organ Involvement and Disease Burden. <i>Blood</i> , 2016, 128, 3273-3273.	4.2	0
263	Changes in Uninvolved Immunoglobulins during Multiple Myeloma Therapy. <i>Blood</i> , 2016, 128, 3251-3251.	4.2	0
264	Survival Trends in Young Patients with Waldenstrom Macroglobulinemia: Over 5 Decades of Experience. <i>Blood</i> , 2016, 128, 1810-1810.	4.2	0
265	Beta-Blockers Improved Survival Outcomes in Patients with Multiple Myeloma: A Retrospective Evaluation. <i>Blood</i> , 2016, 128, 3306-3306.	4.2	0
266	The Prognostic Significance of Polyclonal Bone Marrow Plasma Cells in Patients with Actively Relapsing Multiple Myeloma. <i>Blood</i> , 2016, 128, 1194-1194.	4.2	0
267	Fluorescence in-Situ Hybridization (FISH) Analysis in Untreated AL Amyloidosis Has an Independent Prognostic Impact By Abnormality Type and Treatment Category. <i>Blood</i> , 2016, 128, 3269-3269.	4.2	0
268	Treatment Patterns and Outcomes Following Initial Relapse in Patients with Relapsed Systemic Immunoglobulin Light Chain Amyloidosis. <i>Blood</i> , 2016, 128, 3338-3338.	4.2	0
269	Predicting Poor Overall Survival in Patients with Newly Diagnosed Multiple Myeloma and Standard-Risk Cytogenetics Treated with Novel Agents. <i>Blood</i> , 2016, 128, 3255-3255.	4.2	0
270	Outcome of Very Young (â‰¥ 40 years) Patients with Immunoglobulin Light Chain Amyloidosis (AL): A Case Control Study. <i>Blood</i> , 2016, 128, 5576-5576.	4.2	2

#	ARTICLE	IF	PR CITATIONS
271	Lenalidomide and Low Dose Dexamethasone in Previously Treated Multiple Myeloma Patients with Impaired Renal Function: Efficacy Analysis of PrE1003, a Precog Study. <i>Blood</i> , 2016, 128, 5712-5712.	4.2	0
272	Melphalan, prednisone, and thalidomide vs melphalan, prednisone, and lenalidomide (ECOG E1A06) in untreated multiple myeloma. <i>Blood</i> , 2015, 126, 1294-1301.	4.2	85
273	Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. <i>Blood</i> , 2015, 125, 2068-2074.	4.2	699
274	Macro-Quest. <i>Blood</i> , 2015, 125, 2318-2319.	4.2	3
275	Predictors of early response to initial therapy in patients with newly diagnosed symptomatic multiple myeloma. <i>American Journal of Hematology</i> , 2015, 90, 888-891.	6.1	20
276	Outcomes of primary refractory multiple myeloma and the impact of novel therapies. <i>American Journal of Hematology</i> , 2015, 90, 981-985.	6.1	42
277	Evolving diagnostic criteria for multiple myeloma. <i>Hematology American Society of Hematology Education Program</i> , 2015, 2015, 272-278.	2.9	56
278	Elevation of Serum Immunoglobulin Free Light Chains During the Preclinical Period of Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2015, 42, 181-187.	2.4	23
279	Kinetics of organ response and survival following normalization of the serum free light chain ratio in AL amyloidosis. <i>American Journal of Hematology</i> , 2015, 90, 181-186.	6.1	85
280	Monitoring IgA Multiple Myeloma: Immunoglobulin Heavy/Light Chain Assays. <i>Clinical Chemistry</i> , 2015, 61, 360-367.	1.1	64
281	Role of Magnetic Resonance Imaging in the Management of Patients With Multiple Myeloma: A Consensus Statement. <i>Journal of Clinical Oncology</i> , 2015, 33, 657-664.	21.6	370
282	Clinical course and prognosis of nonsecretory multiple myeloma. <i>European Journal of Haematology</i> , 2015, 95, 57-64.	1.9	70
283	Trends and Racial/Ethnic Disparities in Gluten-Sensitive Problems in the United States: Findings from the National Health and Nutrition Examination Surveys From 1988 to 2012. <i>American Journal of Gastroenterology</i> , 2015, 110, 455-461.	0.7	112
284	Hematologic Characteristics of Proliferative Glomerulonephritides With Nonorganized Monoclonal Immunoglobulin Deposits. <i>Mayo Clinic Proceedings</i> , 2015, 90, 587-596.	3.1	113
285	Treatment of Immunoglobulin Light Chain Amyloidosis. <i>Mayo Clinic Proceedings</i> , 2015, 90, 1054-1081.	3.1	113
286	Bortezomib-induced acute interstitial nephritis. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 1225-1229.	0.8	31
287	Smoldering multiple myeloma. <i>Blood</i> , 2015, 125, 3069-3075.	4.2	259
288	Soluble suppression of tumorigenicity 2 (sST <sub>2</sub> ), but not galactin-3, adds to prognostication in patients with systemic AL amyloidosis independent of NT-proBNP and troponin T. <i>American Journal of Hematology</i> , 2015, 90, 524-528.	6.1	40

#	ARTICLE	IF	PR CITATIONS
289	Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma. <i>New England Journal of Medicine</i> , 2015, 372, 142-152.	43.7	1,266
290	Multiple myeloma after kidney transplantation. <i>Clinical Transplantation</i> , 2015, 29, 76-84.	1.7	18
291	In Patients with Light-Chain (AL) Amyloidosis Myocardial Contraction Fraction (MCF) Is a Simple, but Powerful Prognostic Measure That Can be Calculated from a Standard Echocardiogram (ECHO). <i>Blood</i> , 2015, 126, 1774-1774.	4.2	6
292	Necrobiotic Xanthogranuloma (NXG) Associated with Monoclonal Gammopathies (MG): Clinical Features and Treatment Outcomes. <i>Blood</i> , 2015, 126, 1830-1830.	4.2	1
293	Bortezomib, Lenalidomide and Dexamethasone Vs. Lenalidomide and Dexamethasone in Patients (Pts) with Previously Untreated Multiple Myeloma without an Intent for Immediate Autologous Stem Cell Transplant (ASCT): Results of the Randomized Phase III Trial SWOG S0777. <i>Blood</i> , 2015, 126, 25-25.	4.2	47
294	Randomized Phase 2 Trial of Two Different Doses of Ixazomib in Patients with Relapsed Multiple Myeloma Not Refractory to Bortezomib. <i>Blood</i> , 2015, 126, 3050-3050.	4.2	8
295	Impact of Bone Marrow Plasmacytosis on Outcome in Patients with AL Amyloidosis Following Autologous Stem Cell Transplant. <i>Blood</i> , 2015, 126, 3177-3177.	4.2	4
296	Presentation and Outcomes of Localized Amyloidosis: The Mayo Clinic Experience. <i>Blood</i> , 2015, 126, 4197-4197.	4.2	5
297	Impact of Cytogenetics on Outcomes of Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Continuous Lenalidomide Plus Low-Dose Dexamethasone in the First (MM-020) Trial. <i>Blood</i> , 2015, 126, 730-730.	4.2	15
298	Outcome with Lenalidomide Plus Dexamethasone Followed By Early Autologous Stem Cell Transplantation in the ECOG-ACRIN E4A03 Randomized Clinical Trial: Long-Term Follow-up. <i>Blood</i> , 2015, 126, 3174-3174.	4.2	0
299	Scattome: A Single-Cell Analysis of Targeted Transcriptome Program to Predict Drug Sensitivity of Single Cells within Human Myeloma Tumors. <i>Blood</i> , 2015, 126, 4249-4249.	4.2	1
300	N-Terminal Fragment of the Type-B Natriuretic Peptide (NT-proBNP) Is a Prognostic Factor for Overall Survival in Newly Diagnosed Patients with Multiple Myeloma (MM). <i>Blood</i> , 2015, 126, 3292-3292.	4.2	0
301	AL Amyloidosis and Patient Reported Quality of Life. <i>Blood</i> , 2015, 126, 3317-3317.	4.2	0
302	Occurrence and Prognostic Significance of Cytogenetic Evolution in Patients with Multiple Myeloma. <i>Blood</i> , 2015, 126, 4176-4176.	4.2	0
303	Natural History of Amyloidosis Isolated to Fat and Bone Marrow Aspirate. <i>Blood</i> , 2015, 126, 5303-5303.	4.2	0
304	Long-term disease control in patients with newly diagnosed multiple myeloma after suspension of lenalidomide therapy. <i>American Journal of Hematology</i> , 2014, 89, 302-305.	6.1	5
305	Immunoglobulin light chain amyloidosis is diagnosed late in patients with preexisting plasma cell dyscrasias. <i>American Journal of Hematology</i> , 2014, 89, 1051-1054.	6.1	38
306	Protein Electrophoresis and Immunofixation for the Diagnosis of Monoclonal Gammopathies. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 2160.	17.1	3

#	ARTICLE	IF	PR CITATIONS
307	International Myeloma Working Group Consensus Statement for the Management, Treatment, and Supportive Care of Patients With Myeloma Not Eligible for Standard Autologous Stem-Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2014, 32, 587-600.	21.6	373
308	Outcomes and treatments of patients with immunoglobulin light chain amyloidosis who progress or relapse postautologous stem cell transplant. <i>European Journal of Haematology</i> , 2014, 92, 485-490.	1.9	23
309	Multiple myeloma: 2014 Update on diagnosis, risk stratification, and management. <i>American Journal of Hematology</i> , 2014, 89, 998-1009.	6.1	157
310	Multiple mechanisms contribute to the synergistic anti-myeloma activity of the pan-histone deacetylase inhibitor LBH589 and the rapalog RAD001. <i>Leukemia Research</i> , 2014, 38, 1358-1366.	0.7	13
311	Clinical course of light-chain smouldering multiple myeloma (idiopathic Bence Jones proteinuria): a retrospective cohort study. <i>Lancet Haematology</i> , 2014, 1, e28-e36.	9.2	49
312	International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. <i>Lancet Oncology</i> , 2014, 15, e538-e548.	26.0	4,298
313	Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma. <i>Hematology/Oncology Clinics of North America</i> , 2014, 28, 775-790.	2.3	41
314	The clinical significance of cereblon expression in multiple myeloma. <i>Leukemia Research</i> , 2014, 38, 23-28.	0.7	99
315	Trends in survival of patients with primary plasma cell leukemia: a population-based analysis. <i>Blood</i> , 2014, 124, 907-912.	4.2	131
316	Development and Results of a Multiple Myeloma Specific Custom 77-Gene Mutation Panel for Clinical Targeted Sequencing. <i>Blood</i> , 2014, 124, 169-169.	4.2	3
317	Measurement of the Proliferation of Clonal Plasma Cells By Multiparametric Flow Cytometry Is a Clinically Useful Tool in Multiple Myeloma. <i>Blood</i> , 2014, 124, 2053-2053.	4.2	1
318	Pomalidomide, Bortezomib and Dexamethasone (PVD) for Patients with Relapsed Lenalidomide Refractory Multiple Myeloma (MM). <i>Blood</i> , 2014, 124, 304-304.	4.2	25
319	PET-CT Has Major Diagnostic Value in the Evaluation of Smoldering Multiple Myeloma. <i>Blood</i> , 2014, 124, 3382-3382.	4.2	4
320	SWOG 1211: Initial Report on PHASE I Trial of RVD-Elotuzumab for NEWLY Diagnosed High Risk Multiple Myeloma (HRMM). <i>Blood</i> , 2014, 124, 4762-4762.	4.2	4
321	Carfilzomib, Lenalidomide, and Dexamethasone vs Lenalidomide and Dexamethasone in Patients (Pts) with Relapsed Multiple Myeloma: Interim Results from ASPIRE, a Randomized, Open-Label, Multicenter Phase 3 Study. <i>Blood</i> , 2014, 124, 79-79.	4.2	15
322	Adverse Cytogenetics, with or without Trisomies, in Patients Undergoing High Dose Therapy for Multiple Myeloma and Impact of Post-Transplant Maintenance Therapy. <i>Blood</i> , 2014, 124, 3456-3456.	4.2	0
323	Pomalidomide Plus Low-Dose Dexamethasone (Pom/Dex) in Relapsed Lenalidomide Refractory Myeloma: Long Term Follow up and Comparison of 2 Mg Vs 4 Mg Doses. <i>Blood</i> , 2014, 124, 4780-4780.	4.2	0
324	Impact of Beta Blocker on Clinical Outcomes of Multiple Myeloma (MM) Patients. <i>Blood</i> , 2014, 124, 4751-4751.	4.2	0

#	ARTICLE	IF	PR CITATIONS
325	Impact of Novel Agents on Young Patients with t(11;14) Multiple Myeloma. <i>Blood</i> , 2014, 124, 2059-2059.	4.2	1
326	Primary systemic amyloidosis. <i>Current Treatment Options in Oncology</i> , 2013, 3, 261-271.	4.2	17
327	Smoldering multiple myeloma requiring treatment: time for a new definition?. <i>Blood</i> , 2013, 122, 4172-4181.	4.2	77
328	Treatment trade-offs in myeloma: A survey of consecutive patients about contemporary maintenance strategies. <i>Cancer</i> , 2013, 119, 4308-4315.	4.1	15
329	International Myeloma Working Group Recommendations for the Treatment of Multiple Myeloma-Related Bone Disease. <i>Journal of Clinical Oncology</i> , 2013, 31, 2347-2357.	21.6	324
330	Responsiveness of cytogenetically discrete human myeloma cell lines to lenalidomide: lack of correlation with cereblon and interferon regulatory factor 4 expression levels. <i>European Journal of Haematology</i> , 2013, 91, 504-513.	1.9	15
331	Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma. <i>Blood</i> , 2013, 121, 884-892.	4.2	160
332	Monoclonal Gammopathy-Associated Proliferative Glomerulonephritis. <i>Mayo Clinic Proceedings</i> , 2013, 88, 1284-1293.	3.1	88
333	In reply. <i>Mayo Clinic Proceedings</i> , 2013, 88, 306-307.	3.1	0
334	Management of Newly Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 2013. <i>Mayo Clinic Proceedings</i> , 2013, 88, 360-376.	3.1	494
335	Immunoglobulin M Monoclonal Gammopathy of Undetermined Significance and Smoldering Waldenström Macroglobulinemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 184-186.	1.0	19
336	Multiple myeloma: 2013 update on diagnosis, risk-stratification, and management. <i>American Journal of Hematology</i> , 2013, 88, 225-235.	6.1	107
337	A detailed evaluation of the current renal response criteria in AL amyloidosis: is it time for a revision?. <i>Haematologica</i> , 2013, 98, 988-992.	4.1	51
338	IV. Initial treatment of multiple myeloma. <i>Hematological Oncology</i> , 2013, 31, 33-37.	2.2	6
339	Differences in the distribution of cytogenetic subtypes between multiple myeloma patients with and without a family history of monoclonal gammopathy and multiple myeloma. <i>European Journal of Haematology</i> , 2013, 91, 193-195.	1.9	3
340	Uncovering the biology of multiple myeloma among African Americans: a comprehensive genomics approach. <i>Blood</i> , 2013, 121, 3147-3152.	4.2	60
341	Outcomes of patients with POEMS syndrome treated initially with radiation. <i>Blood</i> , 2013, 122, 68-73.	4.2	86
342	Therapy Related MDS/AML In Multiple Myeloma Patients In The Era Of Novel Agents. <i>Blood</i> , 2013, 122, 3117-3117.	4.2	2

#	ARTICLE	IF	PR CITATIONS
343	Phase II Trial Of Initial Safety and Toxicity Prior To The Phase III Trial Of Lenalidomide Versus Observation Alone In Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma (E3A06): A Trial Coordinated By The Eastern Cooperative Oncology Group. <i>Blood</i> , 2013, 122, 3174-3174.	4.2	2
344	Impact Of FISH Abnormalities On Response To Lenalidomide In Patients With Multiple Myeloma. <i>Blood</i> , 2013, 122, 3210-3210.	4.2	9
345	Lenalidomide Maintenance Therapy In Multiple Myeloma: A Meta-Analysis Of Randomized Trials. <i>Blood</i> , 2013, 122, 407-407.	4.2	13
346	Effect Of Immediate Prior-Line Lenalidomide Or Thalidomide Therapy On Response To Pomalidomide In Multiple Myeloma. <i>Blood</i> , 2013, 122, 1979-1979.	4.2	0
347	Prognostic Value Of Quantifying Circulating Plasma Cells By Multiparametric Flow Cytometry In Patients With Relapsed Multiple Myeloma. <i>Blood</i> , 2013, 122, 754-754.	4.2	0
348	A Meta-Analysis Of Genome-Wide Association Studies Of Multiple Myeloma In Cases and Controls Of European Origin Identifies a Risk Locus In 12q23.1. <i>Blood</i> , 2013, 122, 3111-3111.	4.2	2
349	Responsiveness Of Cytogenetically Discrete Human Myeloma Cell Lines To Lenalidomide: Lack Of Correlation With Cereblon and Interferon Regulatory Factor 4 Expression Levels. <i>Blood</i> , 2013, 122, 1962-1962.	4.2	0
350	Increased Circulating Plasma Cells On Multiparametric Flow Cytometry As An Independent Prognostic Biomarker In Newly Diagnosed Multiple Myeloma: Implications For Redefining High-Risk Myeloma. <i>Blood</i> , 2013, 122, 1842-1842.	4.2	0
351	Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. <i>Blood</i> , 2012, 119, 4375-4382.	4.2	431
352	Laboratory Persistence and Clinical Progression of Small Monoclonal Abnormalities. <i>American Journal of Clinical Pathology</i> , 2012, 138, 609-613.	0.8	48
353	Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis. <i>Blood</i> , 2012, 119, 5397-5404.	4.2	155
354	Urinary Albumin Excretion Patterns of Patients with Cast Nephropathy and Other Monoclonal Gammopathy-Related Kidney Diseases. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2012, 7, 1964-1968.	4.4	82
355	Immunoglobulin D amyloidosis: a distinct entity. <i>Blood</i> , 2012, 119, 44-48.	4.2	18
356	High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvement. <i>Blood</i> , 2012, 119, 1117-1122.	4.2	84
357	Progression in smoldering Waldenström macroglobulinemia: long-term results. <i>Blood</i> , 2012, 119, 4462-4466.	4.2	132
358	Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial. <i>Blood</i> , 2012, 119, 4860-4867.	4.2	124
359	Second to none. <i>Blood</i> , 2012, 120, 1537-1539.	4.2	6
360	Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics. <i>Blood</i> , 2012, 119, 2100-2105.	4.2	239

#	ARTICLE	IF	PR CITATIONS
361	Use of Nonclonal Serum Immunoglobulin Free Light Chains to Predict Overall Survival in the General Population. <i>Mayo Clinic Proceedings</i> , 2012, 87, 517-523.	3.1	118
362	Bortezomib Combination Therapy in Multiple Myeloma. <i>Seminars in Hematology</i> , 2012, 49, 228-242.	3.2	70
363	Incidence of Monoclonal Gammopathy of Undetermined Significance and Estimation of Duration Before First Clinical Recognition. <i>Mayo Clinic Proceedings</i> , 2012, 87, 1071-1079.	3.1	114
364	Doublets, triplets, or quadruplets of novel agents in newly diagnosed myeloma?. <i>Hematology American Society of Hematology Education Program</i> , 2012, 2012, 354-361.	2.9	30
365	Trends and outcomes of modern staging of solitary plasmacytoma of bone. <i>American Journal of Hematology</i> , 2012, 87, 647-651.	6.1	80
366	Familial monoclonal gammopathy of undetermined significance and multiple myeloma: epidemiology, risk factors, and biological characteristics. <i>Blood</i> , 2012, 119, 5359-5366.	4.2	76
367	Clonal competition with alternating dominance in multiple myeloma. <i>Blood</i> , 2012, 120, 1067-1076.	4.2	600
368	Elucidating disparities across racial and ethnic groups in multiple myeloma patients. <i>International Journal of Hematology</i> , 2012, 95, 453-454.	1.6	3
369	A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myeloma. <i>British Journal of Haematology</i> , 2012, 156, 326-333.	2.4	51
370	Clinicopathologic Correlations in Multiple Myeloma: A Case Series of 190 Patients With Kidney Biopsies. <i>American Journal of Kidney Diseases</i> , 2012, 59, 786-794.	1.4	197
371	Evaluation of pretransplant factors predicting cardiac dysfunction following high-dose melphalan conditioning and autologous peripheral blood stem cell transplantation. <i>European Journal of Haematology</i> , 2012, 89, 228-235.	1.9	12
372	Early versus delayed autologous transplantation after immunomodulatory agent-based induction therapy in patients with newly diagnosed multiple myeloma. <i>Cancer</i> , 2012, 118, 1585-1592.	4.1	111
373	Multiple myeloma: 2012 update on diagnosis, risk stratification, and management. <i>American Journal of Hematology</i> , 2012, 87, 78-88.	6.1	122
374	Sorafenib, a multikinase inhibitor, is effective in vitro against non-Hodgkin lymphoma and synergizes with the mTOR inhibitor rapamycin. <i>American Journal of Hematology</i> , 2012, 87, 277-283.	6.1	29
375	Cereblon Expression Predicts Response, Progression Free and Overall Survival After Pomalidomide and Dexamethasone Therapy in Multiple Myeloma. <i>Blood</i> , 2012, 120, 194-194.	4.2	11
376	Pomalidomide Plus Low-Dose Dexamethasone (Pom/Dex) in Relapsed Myeloma: Long Term Follow up and Factors Predicting Outcome in 345 Patients. <i>Blood</i> , 2012, 120, 201-201.	4.2	18
377	Doxycycline Used As Post Transplant Antibacterial Prophylaxis Improves Survival in Patients with Light Chain Amyloidosis Undergoing Autologous Stem Cell Transplantation.. <i>Blood</i> , 2012, 120, 3138-3138.	4.2	29
378	Continued Improvement in Survival in Multiple Myeloma and the Impact of Novel Agents. <i>Blood</i> , 2012, 120, 3972-3972.	4.2	9

#	ARTICLE	IF	PR CITATIONS
379	Phase II Trial of Initial Safety and Toxicity Prior to the Phase III Trial of Lenalidomide Versus Observation Alone in Patients with Asymptomatic High-Risk Smoldering Multiple Myeloma (E3A06): A Trial Coordinated by the Eastern Cooperative Oncology Group. <i>Blood</i> , 2012, 120, 4079-4079.	4.2	1
380	Survival After Second, Third, and Fourth Line Therapy Better Than Expected in Patients with Previously Treated AL Amyloidosis Who Were Not Transplant Candidates At Diagnosis.. <i>Blood</i> , 2012, 120, 946-946.	4.2	1
381	Anti-Myeloma Activity of Akt Inhibition Is Linked to the Activation Status of PI3K/Akt and MEK/ERK Pathway. <i>PLoS ONE</i> , 2012, 7, e50005.	2.4	56
382	Upfront Therapy for Myeloma: Tailoring Therapy across the Disease Spectrum. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2012, , 508-514.	4.6	1
383	Phase 1b/2a Open-Label, Multiple-Dose, Dose-Escalation Study to Evaluate the Safety and Tolerability of SNS01-T Administered by Intravenous Infusion in Patients with Relapsed or Refractory Multiple Myeloma.. <i>Blood</i> , 2012, 120, 2973-2973.	4.2	16
384	Outcomes of Patients with POEMS Syndrome Treated Initially with Radiation. <i>Blood</i> , 2012, 120, 448-448.	4.2	0
385	A Phase I/II Study of the Tolerability of Lenalidomide and Low Dose Dexamethasone in Previously Treated Multiple Myeloma Patients with Impaired Renal Function: Pre1003, a Precog LLC Study. <i>Blood</i> , 2012, 120, 1856-1856.	4.2	7
386	Preclinical Evaluation of AT219, a Small Molecule Inhibitor of MDM2 As an Anti-Myeloma Agent.. <i>Blood</i> , 2012, 120, 2948-2948.	4.2	0
387	Development of Myelodysplastic Syndrome and Acute Leukemias in Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS): A Population-Based Study of 17,315 Patients. <i>Blood</i> , 2012, 120, 934-934.	4.2	0
388	Simultaneous Inhibition of cIAP1, cIAP2 and XIAP Is Required for Inducing Apoptosis in Multiple Myeloma Cells.. <i>Blood</i> , 2012, 120, 2943-2943.	4.2	0
389	Promising Pre-Clinical Activity of A-1014907, a Dual Inhibitor of Aurora Kinases and VEGFR in Multiple Myeloma. <i>Blood</i> , 2012, 120, 1848-1848.	4.2	0
390	Idiopathic Bence Jones Proteinuria (Smoldering Monoclonal Light-Chain Proteinuria): Clinical Course and Prognosis. <i>Blood</i> , 2012, 120, 1861-1861.	4.2	2
391	Treatment Trade-Offs in Myeloma: a Survey of Consecutive Patients. <i>Blood</i> , 2012, 120, 2059-2059.	4.2	0
392	Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. <i>Blood</i> , 2011, 117, 4701-4705.	4.2	403
393	Incidence, clinical course, and prognosis of secondary monoclonal gammopathy of undetermined significance in patients with multiple myeloma. <i>Blood</i> , 2011, 118, 2985-2987.	4.2	37
394	Recent Improvements in Survival in Primary Systemic Amyloidosis and the Importance of an Early Mortality Risk Score. <i>Mayo Clinic Proceedings</i> , 2011, 86, 12-18.	3.1	182
395	Early Reduction of Serum-Free Light Chains Associates with Renal Recovery in Myeloma Kidney. <i>Journal of the American Society of Nephrology: JASN</i> , 2011, 22, 1129-1136.	0.4	214
396	Effects of Lenalidomide and Dexamethasone Treatment Duration on Survival in Patients With Relapsed or Refractory Multiple Myeloma Treated With Lenalidomide and Dexamethasone. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 38-43.	1.0	59

#	ARTICLE	IF	PR CITATIONS
397	IgM Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Waldenström's Macroglobulinemia (SWM). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 74-76.	1.0	41
398	Development of Early Treatment Strategies for High-Risk Myeloma Precursor Disease in the Future. <i>Seminars in Hematology</i> , 2011, 48, 66-72.	3.2	9
399	Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. <i>Blood</i> , 2011, 117, 4691-4695.	4.2	953
400	Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. <i>Blood</i> , 2011, 117, 4696-4700.	4.2	299
401	International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. <i>Blood</i> , 2011, 117, 6063-6073.	4.2	295
402	Reduction in plasma cell proliferation after initial therapy in newly diagnosed multiple myeloma measures treatment response and predicts improved survival. <i>Blood</i> , 2011, 118, 2702-2707.	4.2	24
403	Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasone. <i>Blood</i> , 2011, 118, 4359-4362.	4.2	43
404	Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. <i>Blood</i> , 2011, 118, 2970-2975.	4.2	201
405	Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myeloma. <i>Blood</i> , 2011, 118, 1763-1765.	4.2	61
406	Bone microstructural changes revealed by high-resolution peripheral quantitative computed tomography imaging and elevated DKK1 and MIP-1 $\beta$ levels in patients with MGUS. <i>Blood</i> , 2011, 118, 6529-6534.	4.2	70
407	Approach to the treatment of multiple myeloma: a clash of philosophies. <i>Blood</i> , 2011, 118, 3205-3211.	4.2	142
408	Impact of high-risk classification by FISH: an Eastern Cooperative Oncology Group (ECOG) study E4A03. <i>British Journal of Haematology</i> , 2011, 155, 340-348.	2.4	30
409	Initial genome sequencing and analysis of multiple myeloma. <i>Nature</i> , 2011, 471, 467-472.	38.7	1,350
410	Asymptomatic immunoglobulin light chain amyloidosis (AL) at the time of diagnostic bone marrow biopsy in newly diagnosed patients with multiple myeloma and smoldering myeloma. A series of 144 cases and a review of the literature. <i>Annals of Hematology</i> , 2011, 90, 101-106.	1.5	47
411	Update on risk stratification and treatment of newly diagnosed multiple myeloma. <i>International Journal of Hematology</i> , 2011, 94, 310-320.	1.6	33
412	Multiple myeloma: 2011 update on diagnosis, risk stratification, and management. <i>American Journal of Hematology</i> , 2011, 86, 57-65.	6.1	145
413	Changes in serum free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosis. <i>American Journal of Hematology</i> , 2011, 86, 251-255.	6.1	81
414	High prevalence of polyclonal hypergammaglobulinemia in adult males in Ghana, Africa. <i>American Journal of Hematology</i> , 2011, 86, 554-558.	6.1	16

#	ARTICLE	IF	PR CITATIONS
415	Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: Results from a phase 2 trial. American Journal of Hematology, 2011, 86, 640-645.	6.1	58
416	From Myeloma Precursor Disease to Multiple Myeloma: New Diagnostic Concepts and Opportunities for Early Intervention. Clinical Cancer Research, 2011, 17, 1243-1252.	6.9	77
417	Long-Term Biological Variation of Serum Protein Electrophoresis M-Spike, Urine M-Spike, and Monoclonal Serum Free Light Chain Quantification: Implications for Monitoring Monoclonal Gammopathies. Clinical Chemistry, 2011, 57, 1687-1692.	1.1	72
418	Treatment of multiple myeloma. Nature Reviews Clinical Oncology, 2011, 8, 479-491.	75.5	266
419	Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study. Leukemia, 2011, 26, 149-157.	10.4	708
420	A Pilot Program in Collaboration with African American Churches Successfully Increases Awareness of the Importance of Cancer Research and Participation in Cancer Translational Research Studies among African Americans. Journal of Cancer Education, 2011, 27, 294-298.	1.1	9
421	Renal Function Measures Improve on Lenalidomide and Dexamethasone and Compete with Patient Characteristics to Predict Lenalidomide Dose Density and Hematologic Toxicity: An E4A03 Analysis. Blood, 2011, 118, 1882-1882.	4.2	2
422	The Utility of High Sensitivity Cardiac Troponin Among Patients with Immunoglobulin Light Chain Amyloidosis. Blood, 2011, 118, 2887-2887.	4.2	1
423	Long Term Outcomes of Pomalidomide and Dexamethasone in Patients with Relapsed Multiple Myeloma: Analysis 4 Years After the Original Cohort. Blood, 2011, 118, 2942-2942.	4.2	2
424	Survival Outcome of Young Multiple Myeloma (MM) Patients in the Era of Novel Therapies. Blood, 2011, 118, 2950-2950.	4.2	1
425	Pomalidomide and Dexamethasone in Relapsed Myeloma: Results of 225 Patients Treated in Five Cohorts Over Three Years,. Blood, 2011, 118, 3963-3963.	4.2	4
426	Long Term Follow-up of IL-1 Receptor Antagonist and Dexamethasone Phase II Clinical Trial in Patients with Smoldering/Indolent Myeloma Shows Improved Survival in Responsive Patients: Implications for Targeting Interleukin-1 Induced IL-6 Production and the Myeloma Proliferative Component. Blood, 2011, 118, 2945-2945.	4.2	2
427	The Depth of Renal Response Strongly Predicts Overall Survival in Patients with AL Amyloidosis. Blood, 2011, 118, 2868-2868.	4.2	8
428	Racial Disparities in Cytogenetic Characteristics and Outcome of Multiple Myeloma. Blood, 2011, 118, 1808-1808.	4.2	0
429	IgD Amyloidosis: An Unrecognized Entity. Blood, 2011, 118, 5079-5079.	4.2	0
430	Serum Free Light Chain Ratio in Distinguishing Smoldering Multiple Myeloma From Active Multiple Myeloma,. Blood, 2011, 118, 3948-3948.	4.2	0
431	Differences in Patterns of Treatment and Outcome Among Patients with Relapsed Refractory Myeloma From United States, Europe and Asia,. Blood, 2011, 118, 3989-3989.	4.2	0
432	Treatment Patterns and Outcomes in Elderly Patients with Multiple Myeloma,. Blood, 2011, 118, 3980-3980.	4.2	1

#	ARTICLE	IF	PR CITATIONS
433	Both Hematologic and Renal Response Affect Overall Survival of Myeloma Patients with Acute Kidney Injury. Blood, 2011, 118, 3949-3949.	4.2	0
434	Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients. Blood, 2010, 115, 1343-1350.	4.2	119
435	Obesity is associated with an increased risk of monoclonal gammopathy of undetermined significance among black and white women. Blood, 2010, 116, 1056-1059.	4.2	155
436	Impact of optimal follow-up of monoclonal gammopathy of undetermined significance on early diagnosis and prevention of myeloma-related complications. Blood, 2010, 116, 2019-2025.	4.2	68
437	Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features. Blood, 2010, 116, 5126-5129.	4.2	160
438	Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma. Current Hematologic Malignancy Reports, 2010, 5, 62-69.	2.8	32
439	Multiple myeloma: chemotherapy or transplantation in the era of new drugs. European Journal of Haematology, 2010, 84, 379-390.	1.9	36
440	Lenalidomide plus dexamethasone vs. lenalidomide plus melphalan and prednisone: a retrospective study in newly diagnosed elderly myeloma. European Journal of Haematology, 2010, 85, 200-208.	1.9	8
441	Residual serum monoclonal protein predicts progression-free survival in patients with previously untreated multiple myeloma. Cancer, 2010, 116, 640-646.	4.1	3
442	Serum immunoglobulin free light chain measurements and heavy chain isotype usage provide insight into disease biology in patients with POEMS syndrome. American Journal of Hematology, 2010, 85, 431-434.	6.1	45
443	Clarithromycin (Biaxin) plus lenalidomide plus low-dose dexamethasone (BiRd) versus lenalidomide plus low-dose dexamethasone (Rd) for newly diagnosed myeloma. American Journal of Hematology, 2010, 85, 664-669.	6.1	49
444	Long-term results of single-agent thalidomide as initial therapy for asymptomatic (smoldering or) Tj ETQq0 0 0 rBT /Overlock 10 Tf	8.1	24
445	Discordance between serum cardiac biomarker and immunoglobulin free light chain response in patients with immunoglobulin light chain amyloidosis treated with immune modulatory drugs. American Journal of Hematology, 2010, 85, 757-759.	6.1	119
446	How best to use new therapies in multiple myeloma. Blood Reviews, 2010, 24, 91-100.	5.2	12
447	Impact of dexamethasone responsiveness on long term outcome in patients with newly diagnosed multiple myeloma. British Journal of Haematology, 2010, 148, 853-858.	2.4	13
448	In Reply. Clinical Chemistry, 2010, 56, 679-680.	1.1	0
449	Smoldering (Asymptomatic) Multiple Myeloma: Current Diagnostic Criteria, New Predictors of Outcome, and Follow-Up Recommendations. Journal of Clinical Oncology, 2010, 28, 690-697.	21.6	106
450	Clinical Features and Treatment Response of Light Chain (AL) Amyloidosis Diagnosed in Patients With Previous Diagnosis of Multiple Myeloma. Mayo Clinic Proceedings, 2010, 85, 232-238.	3.1	90

#	ARTICLE	IF	PR CITATIONS
451	Conflicts of Interest, Authorship, and Disclosures in Industry-Related Scientific Publicationsâ€“2. Mayo Clinic Proceedings, 2010, 85, 197-199.	3.1	5
452	Prevalence of Monoclonal Gammopathy of Undetermined Significance: A Systematic Review. Mayo Clinic Proceedings, 2010, 85, 933-942.	3.1	210
453	Renal Impairment in Patients With Multiple Myeloma: A Consensus Statement on Behalf of the International Myeloma Working Group. Journal of Clinical Oncology, 2010, 28, 4976-4984.	21.6	384
454	Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study. Lancet, The, 2010, 375, 1721-1728.	52.8	359
455	Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncology, The, 2010, 11, 29-37.	26.0	928
456	Optimising bortezomib in newly diagnosed multiple myeloma. Lancet Oncology, The, 2010, 11, 909-910.	26.0	6
457	Higher Plasma Cell Burden Predicts for Early Death In Patients with AL Amyloidosis. Blood, 2010, 116, 1893-1893.	4.2	1
458	Efficacy of Retreatment with Immunomodulatory Compounds In Patients Receiving Initial Therapy for Newly Diagnosed Multiple Myeloma. Blood, 2010, 116, 1964-1964.	4.2	5
459	A Phase III Randomized Trial of Thalidomide (THAL) Plus Zoledronic Acid (ZLD) Versus Zoledronic Acid Alone In Patients with Early Stage Multiple Myeloma (MC0289). Blood, 2010, 116, 3053-3053.	4.2	1
460	Lenalidomide Plus Low-Dose Dexamethasone (Ld): Superior One and Two Year Survival Regardless of Age Compared to Lenalidomide Plus High-Dose Dexamethasone (LD). Blood, 2010, 116, 308-308.	4.2	8
461	Pre-Stem Cell Transplant Induction Therapy Does Not Affect Post-Transplant Survival In Light Chain (AL) Amyloidosis. Blood, 2010, 116, 370-370.	4.2	4
462	Outcome with Lenalidomide Plus Dexamethasone Followed by Early Autologous Stem Cell Transplantation In the ECOG E4A03 Randomized Clinical Trial. Blood, 2010, 116, 38-38.	4.2	17
463	Non-Clonal Serum Immunoglobulin Free Light Chains (FLC) as Markers of Overall Survival. Blood, 2010, 116, 3893-3893.	4.2	2
464	Novel Three- and Four-Drug Combination Regimens of Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide, for Previously Untreated Multiple Myeloma: Results From the Multi-Center, Randomized, Phase 2 EVOLUTION Study. Blood, 2010, 116, 621-621.	4.2	15
465	Pomalidomide Plus Low-Dose Dexamethasone In Myeloma Refractory to Both Bortezomib and Lenalidomide: Comparison of Two Dosing Strategies In Dual-Refractory Disease. Blood, 2010, 116, 863-863.	4.2	1
466	Reduction In Proliferative Rate of Myeloma Plasma Cells Measured by the Plasma Cell Labeling Index Predicts Improved Survival In Multiple Myeloma. Blood, 2010, 116, 4048-4048.	4.2	0
467	Response to Salvage Therapies and Outcome of Patients with Multiple Myeloma Relapsing After Pomalidomide Therapy. Blood, 2010, 116, 1965-1965.	4.2	0
468	Increased Incidence of Extramedullary Plasmacytomas In Patients with Multiple Myeloma In the Era of Novel Therapy and Effect of Pomalidomide on Extramedullary Disease. Blood, 2010, 116, 3047-3047.	4.2	0

#	ARTICLE	IF	PR CITATIONS
469	A Phase-2 Study of Pomalidomide and Dexamethasone In Previously-Treated Light-Chain (AL) Amyloidosis. <i>Blood</i> , 2010, 116, 987-987.	4.2	1
470	Investigational Agent MLN2238/MLN9708, a Specific, Orally Available, Small Molecule Proteasome Inhibitor, Shows Promising In Vitro Activity Against Multiple Myeloma Cell Lines. <i>Blood</i> , 2010, 116, 3014-3014.	4.2	1
471	Mechanism of Action of a Novel c-Met Inhibitor MK2461 In Multiple Myeloma. <i>Blood</i> , 2010, 116, 4078-4078.	4.2	0
472	Significant In Vitro Activity of a Novel Inhibitor of Apoptosis (IAP) Inhibitor LC161 In Multiple Myeloma. <i>Blood</i> , 2010, 116, 2998-2998.	4.2	0
473	Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. <i>Blood</i> , 2009, 113, 5412-5417.	4.2	1,041
474	Screening Panels for Detection of Monoclonal Gammopathies. <i>Clinical Chemistry</i> , 2009, 55, 1517-1522.	1.1	308
475	Clinical outcome of immunoglobulin light chain amyloidosis affecting the kidney. <i>Nephrology Dialysis Transplantation</i> , 2009, 24, 3132-3137.	0.8	118
476	Impact of vitamin D deficiency on the clinical presentation and prognosis of patients with newly diagnosed multiple myeloma. <i>American Journal of Hematology</i> , 2009, 84, 397-400.	6.1	67
477	Idiotype-pulsed antigen presenting cells following autologous transplantation for multiple myeloma may be associated with prolonged survival. <i>American Journal of Hematology</i> , 2009, 84, 799-802.	6.1	88
478	The treatment of multiple myeloma using vincristine, carmustine, melphalan, cyclophosphamide, and prednisone (VBMCP) alternating with high-dose cyclophosphamide and $\gamma$ 2 interferon versus VBMCP. <i>Cancer</i> , 2009, 115, 2155-2164.	4.1	9
479	Prevention of vasa vasorum neovascularization attenuates early neointima formation in experimental hypercholesterolemia. <i>Basic Research in Cardiology</i> , 2009, 104, 695-706.	7.1	63
480	Multiple Myeloma. <i>Current Problems in Cancer</i> , 2009, 33, 7-64.	2.0	69
481	Phase II study of interleukin-12 for treatment of plateau phase multiple myeloma (E1A96): A trial of the Eastern Cooperative Oncology Group. <i>Leukemia Research</i> , 2009, 33, 1485-1489.	0.7	54
482	Treatment of Multiple Myeloma: A Comprehensive Review. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, 278-288.	1.9	144
483	Front-Line Treatment in Younger Patients With Multiple Myeloma. <i>Seminars in Hematology</i> , 2009, 46, 118-126.	3.2	19
484	Disease Associations With Monoclonal Gammopathy of Undetermined Significance: A Population-Based Study of 17,398 Patients. <i>Mayo Clinic Proceedings</i> , 2009, 84, 685-693.	3.1	185
485	Management of Newly Diagnosed Symptomatic Multiple Myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines. <i>Mayo Clinic Proceedings</i> , 2009, 84, 1095-1110.	3.1	416
486	Induction of a Chronic Disease State in Patients With Smoldering or Indolent Multiple Myeloma by Targeting Interleukin $1\beta$ -Induced Interleukin 6 Production and the Myeloma Proliferative Component. <i>Mayo Clinic Proceedings</i> , 2009, 84, 114-122.	3.1	247

#	ARTICLE	IF	PR CITATIONS
487	Pesticide exposure and risk of monoclonal gammopathy of undetermined significance in the Agricultural Health Study. <i>Blood</i> , 2009, 113, 6386-6391.	4.2	150
488	Evidence of serum immunoglobulin abnormalities up to 9.8 years before diagnosis of chronic lymphocytic leukemia: a prospective study. <i>Blood</i> , 2009, 114, 4928-4932.	4.2	79
489	Increased risk of monoclonal gammopathy in first-degree relatives of patients with multiple myeloma or monoclonal gammopathy of undetermined significance. <i>Blood</i> , 2009, 114, 785-790.	4.2	140
490	Translocation t(11;14) and survival of patients with light chain (AL) amyloidosis. <i>Haematologica</i> , 2009, 94, 380-386.	4.1	103
491	Novel Three- and Four-Drug Combinations of Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide, for Newly Diagnosed Multiple Myeloma: Encouraging Results From the Multi-Center, Randomized, Phase 2 EVOLUTION Study.. <i>Blood</i> , 2009, 114, 127-127.	4.2	19
492	Clarithromycin (Biaxin)-Lenalidomide-Low-Dose Dexamethasone (BiRd) Versus Lenalidomide-Low-Dose Dexamethasone (Rd) as Initial Therapy for Newly Diagnosed Multiple Myeloma.. <i>Blood</i> , 2009, 114, 2868-2868.	4.2	3
493	A Phase II Trial of Lenalidomide, Cyclophosphamide and Dexamethasone (RCD) in Patients with Light Chain Amyloidosis.. <i>Blood</i> , 2009, 114, 3853-3853.	4.2	8
494	Melphalan and Prednisone (MP) Versus Melphalan, Prednisone and Thalidomide (MPT) as Initial Therapy for Previously Untreated Elderly and/or Transplant Ineligible Patients with Multiple Myeloma: A Meta-Analysis of Randomized Controlled Trials.. <i>Blood</i> , 2009, 114, 615-615.	4.2	6
495	Novel Agents for Initial Therapy of Multiple Myeloma: Comparable Results with Continued Initial Therapy and Delayed Transplantation at Relapse Versus Early Transplantation.. <i>Blood</i> , 2009, 114, 956-956.	4.2	1
496	Lenalidomide Plus Dexamethasone Versus Lenalidomide Plus Melphalan and Prednisone: A Case-Control Study in Newly Diagnosed Elderly Myeloma Patients.. <i>Blood</i> , 2009, 114, 2877-2877.	4.2	0
497	Superiority of Lenalidomide-Dexamethasone Versus Thalidomide-Dexamethasone as Initial Therapy for Newly Diagnosed Multiple Myeloma.. <i>Blood</i> , 2009, 114, 3884-3884.	4.2	0
498	Asymptomatic Amyloidosis at the Time of Diagnostic Bone Marrow Biopsy in Newly Diagnosed Patients with Multiple Myeloma and Smoldering Multiple Myeloma.. <i>Blood</i> , 2009, 114, 2803-2803.	4.2	0
499	Thromboembolic events with lenalidomide-based therapy for multiple myeloma. <i>Cancer</i> , 2008, 112, 1522-1528.	4.1	83
500	Autologous stem cell transplantation in patients of 70 years and older with multiple myeloma: Results from a matched pair analysis. <i>American Journal of Hematology</i> , 2008, 83, 614-617.	6.1	124
501	Anti-CD20 monoclonal antibody therapy in multiple myeloma. <i>British Journal of Haematology</i> , 2008, 141, 135-148.	2.4	103
502	Outcome after autologous stem cell transplantation for multiple myeloma in patients with preceding plasma cell disorders. <i>British Journal of Haematology</i> , 2008, 141, 205-211.	2.4	21
503	The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma. <i>British Journal of Haematology</i> , 2008, 143, 46-53.	2.4	95
504	Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma. <i>British Journal of Haematology</i> , 2008, 143, 222-229.	2.4	95

#	ARTICLE	IF	PR CITATIONS
505	R-(-)-gossypol (AT-101) activates programmed cell death in multiple myeloma cells. <i>Experimental Hematology</i> , 2008, 36, 568-576.	0.4	60
506	Consolidation Therapy with Bortezomib/Lenalidomide/Dexamethasone Versus Bortezomib/Dexamethasone After a Dexamethasone-Based Induction Regimen in Patients with Multiple Myeloma: A Randomized Phase III Trial. <i>Clinical Lymphoma and Myeloma</i> , 2008, 8, 315-317.	1.9	13
507	Genetic Predisposition for Monoclonal Gammopathy of Undetermined Significance. <i>Mayo Clinic Proceedings</i> , 2008, 83, 602-603.	3.1	0
508	Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure. <i>Blood</i> , 2008, 112, 4445-4451.	4.2	168
509	Autologous Stem Cell Transplant after Heart Transplant for Light Chain (AL) Amyloid Cardiomyopathy. <i>Journal of Heart and Lung Transplantation</i> , 2008, 27, 823-829.	1.2	126
510	Serum Uric Acid: Novel Prognostic Factor in Primary Systemic Amyloidosis. <i>Mayo Clinic Proceedings</i> , 2008, 83, 297-303.	3.1	45
511	Improved survival in multiple myeloma and the impact of novel therapies. <i>Blood</i> , 2008, 111, 2516-2520.	4.2	2,120
512	Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Thalidomide Plus Dexamethasone Compared With Dexamethasone As Initial Therapy for Newly Diagnosed Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2008, 26, 2171-2177.	21.6	335
513	Genetic Predisposition for Monoclonal Gammopathy of Undetermined Significance. <i>Mayo Clinic Proceedings</i> , 2008, 83, 602-603.	3.1	1
514	Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. <i>Blood</i> , 2008, 111, 785-789.	4.2	396
515	Multiple myeloma. <i>Blood</i> , 2008, 111, 2962-2972.	4.2	878
516	Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping. <i>Blood</i> , 2008, 112, 4924-4934.	4.2	64
517	Many facets of bortezomib resistance/susceptibility. <i>Blood</i> , 2008, 112, 2177-2178.	4.2	76
518	Loss of p53 Is a Marker of Progression in Plasma Cell Neoplasias and Is a Negative Prognostic Factor in Relapsed Disease. <i>Blood</i> , 2008, 112, 1663-1663.	4.2	1
519	Prognostic Impact of the Plasma Cell Labeling Index (LI) in Newly Diagnosed Myeloma Patients Treated with Thalidomide-Dexamethasone (Thal/Dex) or Lenalidomide-Dexamethasone (Len/Dex). <i>Blood</i> , 2008, 112, 1729-1729.	4.2	2
520	Effect of Venous Thrombotic Events on Overall Survival in Multiple Myeloma: Analysis of Thrombotic Events Occurring in E4A03A Randomized Trial of Lenalidomide Plus High-Dose Dexamethasone (RD) Versus Lenalidomide Plus Low-Dose Dexamethasone (Rd) in Newly Diagnosed Multiple Myeloma, a Trial Coordinated by the Eastern Cooperative Oncology Group (ECOG). <i>Blood</i> , 2008, 112, 1740-1740.	4.2	5
521	Stem Cell Mobilization Following Initial Therapy with Lenalidomide and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2008, 112, 3467-3467.	4.2	2
522	Longer Duration of Treatment and Maintenance of Best Response with Lenalidomide and Dexamethasone Prolongs Overall Survival in Patients with Relapsed or Refractory Multiple Myeloma. <i>Blood</i> , 2008, 112, 3702-3702.	4.2	6

#	ARTICLE	IF	PR CITATIONS
523	TRAF3 and TNFAIP3, Two Negative Regulators of NF-Kb Signaling Pathways, Are Mutated in Waldenström's Macroglobulinemia. <i>Blood</i> , 2008, 112, 619-619.	4.2	6
524	Pomalidomide (CC4047) Plus Low-Dose Dexamethasone (Pom/dex) Is Highly Effective Therapy in Relapsed Multiple Myeloma. <i>Blood</i> , 2008, 112, 866-866.	4.2	26
525	Phase II Trial of Lenalidomide (Revlimid <sup>®</sup> ) with Cyclophosphamide and Dexamethasone (RCd) for Newly Diagnosed Myeloma. <i>Blood</i> , 2008, 112, 91-91.	4.2	8
526	Safety and Efficacy of Novel Combination Therapy with Bortezomib, Dexamethasone, Cyclophosphamide, and Lenalidomide in Newly Diagnosed Multiple Myeloma: Initial Results from the Phase I/II Multi-Center EVOLUTION Study. <i>Blood</i> , 2008, 112, 93-93.	4.2	17
527	Survival in Patients with Newly Diagnosed Myeloma Undergoing Therapy with Lenalidomide and Dexamethasone: Impact of High-Risk Cytogenetic Risk Status on Outcome. <i>Blood</i> , 2008, 112, 95-95.	4.2	3
528	Mechanisms of the Formation of Multinuclear Malignant Plasma Cells in the Novel AL/MM Human Cell Lines, ALMC-1 and ALMC-2: Implications for Tumor Cell Growth Control. <i>Blood</i> , 2008, 112, 1707-1707.	4.2	0
529	Serum Immunoglobulin Free Light Chain in Primary Amyloidosis: Prognostic Value and Correlations with Clinical Features. <i>Blood</i> , 2008, 112, 2733-2733.	4.2	0
530	Phase II Study of Melphalan, Prednisone and Lenalidomide Combination for Newly Diagnosed Multiple Myeloma Patients Who Are Not Candidates for Stem Cell Transplantation. <i>Blood</i> , 2008, 112, 2769-2769.	4.2	0
531	Clinical Course and Prognosis of Smoldering (Asymptomatic) Waldenström's Macroglobulinemia. <i>Blood</i> , 2008, 112, 2709-2709.	4.2	6
532	The Prevalence of Abnormal Coagulation Parameters in Patients with Newly Diagnosed Primary Systemic Amyloidosis and Its Impact on Outcome. <i>Blood</i> , 2008, 112, 5114-5114.	4.2	0
533	Comparison of Bromocresol Green and Agarose Protein Electrophoresis for Quantitation of Serum Albumin in Multiple Myeloma. <i>Clinical Chemistry</i> , 2007, 53, 1099-1103.	1.1	36
534	Novel Therapy with 2-Methoxyestradiol for the Treatment of Relapsed and Plateau Phase Multiple Myeloma. <i>Clinical Cancer Research</i> , 2007, 13, 6162-6167.	6.9	71
535	The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. <i>Blood</i> , 2007, 109, 465-470.	4.2	269
536	Cancer Symposium for the Practitioner: Introduction to Solid Tumors. <i>Mayo Clinic Proceedings</i> , 2007, 82, 107-109.	3.1	7
537	Epidemiology of the plasma-cell disorders. <i>Best Practice and Research in Clinical Haematology</i> , 2007, 20, 637-664.	1.8	122
538	Prevalence of Monoclonal Gammopathy of Undetermined Significance Among Men in Ghana. <i>Mayo Clinic Proceedings</i> , 2007, 82, 1468-1473.	3.1	167
539	Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma. <i>New England Journal of Medicine</i> , 2007, 356, 2582-2590.	43.7	853
540	Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma. <i>Hematology/Oncology Clinics of North America</i> , 2007, 21, 1093-1113.	2.3	50

#	ARTICLE	IF	PR CITATIONS
541	Management of Newly Diagnosed Myeloma. Hematology/Oncology Clinics of North America, 2007, 21, 1141-1156.	2.3	14
542	Use of Bisphosphonates in Multiple Myeloma: IMWG Response to Mayo Clinic Consensus Statementâ€“Replyâ€“l. Mayo Clinic Proceedings, 2007, 82, 517-518.	3.1	12
543	Long-term Results of Response to Therapy, Time to Progression, and Survival With Lenalidomide Plus Dexamethasone in Newly Diagnosed Myeloma. Mayo Clinic Proceedings, 2007, 82, 1179-1184.	3.1	143
544	Cancer Symposium for the Practitioner: Introduction to Solid Tumors. Mayo Clinic Proceedings, 2007, 82, 107-109.	3.1	10
545	Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America. New England Journal of Medicine, 2007, 357, 2133-2142.	43.7	1,208
546	Multiple myeloma: New staging systems for diagnosis, prognosis and response evaluation. Best Practice and Research in Clinical Haematology, 2007, 20, 665-680.	1.8	43
547	Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. Blood Reviews, 2007, 21, 255-265.	5.2	59
548	Cytokine and chemokine profiles in multiple myeloma; significance of stromal interaction and correlation of IL-8 production with disease progression. Leukemia Research, 2007, 31, 591-598.	0.7	61
549	Monoclonal gammopathy of undetermined significance and smouldering multiple myeloma: emphasis on risk factors for progression. British Journal of Haematology, 2007, 139, 730-743.	2.4	106
550	Renal Manifestations of Plasma Cell Disorders. American Journal of Kidney Diseases, 2007, 50, 155-165.	1.4	35
551	Immunoglobulin Free Light Chain Ratio Is an Independent Risk Factor for Progression of Smoldering Multiple Myeloma.. Blood, 2007, 110, 1487-1487.	4.2	3
552	Phase II Trial of Lenalidomide, Cyclophosphamide, and Dexamethasone (CRd) for Newly Diagnosed Myeloma.. Blood, 2007, 110, 190-190.	4.2	7
553	Activation of MYC Pathway Is a Unifying Pathological Event in the Progression from Monoclonal Gammopathy of Undetermined Significance (MGUS) to Myeloma (MM).. Blood, 2007, 110, 241-241.	4.2	1
554	Monoclonal Gammopathy of Undetermined Significance: Estimated Incidence and Duration Prior to Recognition.. Blood, 2007, 110, 246-246.	4.2	4
555	A Phase II Trial of Myeloma Induction Therapy with Cyclophosphamide, Bortezomib, and Dexamethasone (Cybor-D): Improved Response over Historical Lenalidomide-Dexamethasone Controls.. Blood, 2007, 110, 3601-3601.	4.2	4
556	A Randomized Trial of Lenalidomide Plus High-Dose Dexamethasone (RD) Versus Lenalidomide Plus Low-Dose Dexamethasone (Rd) in Newly Diagnosed Multiple Myeloma (E4A03): A Trial Coordinated by the Eastern Cooperative Oncology Group.. Blood, 2007, 110, 74-74.	4.2	58
557	Delayed Platelet Engraftment and Outcome of Stem Cell Transplant for Multiple Myeloma: Possible Microenvironment Effect?.. Blood, 2007, 110, 939-939.	4.2	1
558	Melphalan and Dexamethasone Is an Effective Therapy for Primary Systemic Amyloidosis.. Blood, 2007, 110, 3608-3608.	4.2	0

#	ARTICLE	IF	PR CITATIONS
559	Effect of Thrombotic Events on Overall Survival in Patients with Newly Diagnosed Myeloma: Analysis from a Randomized Phase III Trial of Thalidomide Plus Dexamethasone Versus Dexamethasone in Newly Diagnosed Multiple Myeloma (E1A00).. Blood, 2007, 110, 2734-2734.	4.2	1
560	Prognostic Value of the Serum Free Light Chain Ratio in Patients with Newly Diagnosed Myeloma: Proposed Incorporation into the International Staging System.. Blood, 2007, 110, 659-659.	4.2	0
561	Outcome after Autologous Stem Cell Transplantation for Multiple Myeloma in Patients with Preceding Plasma Cell Disorders.. Blood, 2007, 110, 945-945.	4.2	0
562	Recurrent Infections in Multiple Myelomaâ€“Replyâ€“I. Mayo Clinic Proceedings, 2006, 81, 568.	3.1	0
563	Monoclonal Gammopathy of Undetermined Significance, WaldenstrÃ¶m Macroglobulinemia, AL Amyloidosis, and Related Plasma Cell Disorders: Diagnosis and Treatment. Mayo Clinic Proceedings, 2006, 81, 693-703.	3.1	191
564	Primary Surgical Therapy for Osteonecrosis of the Jaw Secondary to Bisphosphonate Therapy. Mayo Clinic Proceedings, 2006, 81, 1100-1103.	3.1	79
565	Elimination of the Need for Urine Studies in the Screening Algorithm for Monoclonal Gammopathies by Using Serum Immunofixation and Free Light Chain Assays. Mayo Clinic Proceedings, 2006, 81, 1575-1578.	3.1	202
566	Response to Rituximab in Patients with Type II Cryoglobulinemia. Clinical Lymphoma and Myeloma, 2006, 7, 140-144.	1.9	35
567	Prevalence of Monoclonal Gammopathy of Undetermined Significance. New England Journal of Medicine, 2006, 354, 1362-1369.	43.7	1,297
568	Thalidomide and lenalidomide in the treatment of multiple myeloma. European Journal of Cancer, 2006, 42, 1612-1622.	5.1	115
569	Dermatologic Adverse Effects of Lenalidomide Therapy for Amyloidosis and Multiple Myeloma. Archives of Dermatology, 2006, 142, .	1.6	79
570	Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood, 2006, 107, 3378-3383.	4.2	241
571	Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: a simple risk stratification system. Blood, 2006, 107, 3384-3388.	4.2	72
572	Clinical implication of centrosome amplification in plasma cell neoplasm. Blood, 2006, 107, 3669-3675.	4.2	90
573	Immunoglobulin free light chains and solitary plasmacytoma of bone. Blood, 2006, 108, 1979-1983.	4.2	161
574	A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood, 2006, 108, 3458-3464.	4.2	507
575	Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with WaldenstrÃ¶m macroglobulinaemia. British Journal of Haematology, 2006, 133, 158-164.	2.4	132
576	Monoclonal gammopathy of undetermined significance. British Journal of Haematology, 2006, 134, 573-589.	2.4	213

#	ARTICLE	IF	PR CITATIONS
577	6q deletion discriminates Waldenström macroglobulinemia from IgM monoclonal gammopathy of undetermined significance. <i>Cancer Genetics and Cytogenetics</i> , 2006, 169, 150-153.	1.3	109
578	Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma. <i>Cancer</i> , 2006, 106, 1316-1319.	4.1	137
579	Frequency, Characteristics, and Reversibility of Peripheral Neuropathy During Treatment of Advanced Multiple Myeloma With Bortezomib. <i>Journal of Clinical Oncology</i> , 2006, 24, 3113-3120.	21.6	612
580	A phase II trial of imatinib in patients with refractory/relapsed myeloma. <i>Leukemia and Lymphoma</i> , 2006, 47, 39-42.	1.5	44
581	Natural history of thromboembolism in AL amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2006, 13, 31-36.	4.7	32
582	Phase III Clinical Trial of Thalidomide Plus Dexamethasone Compared With Dexamethasone Alone in Newly Diagnosed Multiple Myeloma: A Clinical Trial Coordinated by the Eastern Cooperative Oncology Group. <i>Journal of Clinical Oncology</i> , 2006, 24, 431-436.	21.6	820
583	Fracture Risk With Multiple Myeloma: A Population-Based Study. <i>Journal of Bone and Mineral Research</i> , 2005, 20, 487-493.	5.0	300
584	MGUS and Smoldering Multiple Myeloma: Update on Pathogenesis, Natural History, and Management. <i>Hematology American Society of Hematology Education Program</i> , 2005, 2005, 340-345.	2.9	84
585	Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma. <i>Blood</i> , 2005, 106, 2977-2981.	4.2	108
586	Multiple myeloma: the death of VAD as initial therapy. <i>Blood</i> , 2005, 106, 2-3.	4.2	25
587	Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma. <i>Blood</i> , 2005, 106, 2276-2279.	4.2	228
588	Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. <i>Blood</i> , 2005, 106, 4050-4053.	4.2	625
589	Successful Treatment of Scleromyxedema With Autologous Peripheral Blood Stem Cell Transplantation. <i>Archives of Dermatology</i> , 2005, 141, .	1.6	62
590	Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma. <i>Cancer</i> , 2005, 104, 2141-2148.	4.1	99
591	Prognostic Value of Circulating Plasma Cells in Monoclonal Gammopathy of Undetermined Significance. <i>Journal of Clinical Oncology</i> , 2005, 23, 5668-5674.	21.6	120
592	Thalidomide and dexamethasone: therapy for multiple myeloma. <i>Expert Review of Anticancer Therapy</i> , 2005, 5, 759-766.	2.6	22
593	Multiple Myeloma: Diagnosis and Treatment. <i>Mayo Clinic Proceedings</i> , 2005, 80, 1371-1382.	3.1	213
594	Introduction to a Cancer Symposium for the Practitioner. <i>Mayo Clinic Proceedings</i> , 2005, 80, 1085-1086.	3.1	7

#	ARTICLE	IF	PR CITATIONS
595	Prognostic Factors and Predictors of Outcome of Immunoglobulin M Monoclonal Gammopathy of Undetermined Significance. <i>Clinical Lymphoma and Myeloma</i> , 2005, 5, 257-260.	1.9	22
596	Monoclonal Gammopathy of Undetermined Significance. <i>Clinical Lymphoma and Myeloma</i> , 2005, 6, 102-114.	1.9	42
597	Proteasome Inhibition As a Novel Therapeutic Target in Human Cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 630-639.	21.6	537
598	Conventional therapy and approach to management. <i>Best Practice and Research in Clinical Haematology</i> , 2005, 18, 585-601.	1.8	6
599	Monoclonal gammopathies of undetermined significance. <i>Best Practice and Research in Clinical Haematology</i> , 2005, 18, 689-707.	1.8	34
600	Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. <i>Blood</i> , 2005, 106, 812-817.	4.2	640
601	Fracture Risk in Monoclonal Gammopathy of Undetermined Significance. <i>Journal of Bone and Mineral Research</i> , 2004, 19, 25-30.	5.0	155
602	Serum Cardiac Troponins and N-Terminal Pro-Brain Natriuretic Peptide: A Staging System for Primary Systemic Amyloidosis. <i>Journal of Clinical Oncology</i> , 2004, 22, 3751-3757.	21.6	897
603	Thalidomide: Current Role in the Treatment of Non-Plasma Cell Malignancies. <i>Journal of Clinical Oncology</i> , 2004, 22, 2477-2488.	21.6	88
604	Presence of monoclonal free light chains in the serum predicts risk of progression in monoclonal gammopathy of undetermined significance. <i>British Journal of Haematology</i> , 2004, 127, 308-310.	2.4	63
605	Cell proliferation of myeloma plasma cells: Comparison of the blood and marrow compartments. <i>American Journal of Hematology</i> , 2004, 77, 7-11.	6.1	26
606	Incidence of multiple myeloma in Olmsted County, Minnesota. <i>Cancer</i> , 2004, 101, 2667-2674.	4.1	194
607	Long-term Follow-up of 241 Patients With Monoclonal Gammopathy of Undetermined Significance: The Original Mayo Clinic Series 25 Years Later. <i>Mayo Clinic Proceedings</i> , 2004, 79, 859-866.	3.1	177
608	Clinical Course of Patients With Relapsed Multiple Myeloma. <i>Mayo Clinic Proceedings</i> , 2004, 79, 867-874.	3.1	351
609	Multiple Myeloma. <i>New England Journal of Medicine</i> , 2004, 351, 1860-1873.	43.7	1,356
610	Identification of genes modulated in multiple myeloma using genetically identical twin samples. <i>Blood</i> , 2004, 103, 1799-1806.	4.2	129
611	Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. <i>Blood</i> , 2004, 104, 1881-1887.	4.2	316
612	Acquired Fanconi syndrome is an indolent disorder in the absence of overt multiple myeloma. <i>Blood</i> , 2004, 104, 40-42.	4.2	137

#	ARTICLE	IF	PR CITATIONS
613	Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angiogenesis inhibitory activity with disease progression. <i>Blood</i> , 2004, 104, 1159-1165.	4.2	137
614	Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study. <i>Blood</i> , 2004, 103, 3960-3963.	4.2	232
615	Angiogenesis in Waldenstrom's macroglobulinemia. <i>Seminars in Oncology</i> , 2003, 30, 262-264.	1.9	16
616	Influence of postoperative acute-phase response on angiogenesis and tumor growth: open vs. laparoscopic-assisted surgery in mice. <i>Journal of Gastrointestinal Surgery</i> , 2003, 7, 783-790.	1.9	52
617	Monoclonal gammopathies of undetermined significance: a review. <i>Immunological Reviews</i> , 2003, 194, 112-139.	6.6	118
618	Bone marrow angiogenesis and circulating plasma cells in multiple myeloma. <i>British Journal of Haematology</i> , 2003, 122, 272-274.	2.4	24
619	Plasma levels of tumour necrosis factor alpha and interleukin-6 predict progression-free survival following thalidomide therapy in patients with previously untreated multiple myeloma. <i>British Journal of Haematology</i> , 2003, 123, 305-308.	2.4	31
620	Use of Bisphosphonates in Patients With Myeloma and Renal Failure—Reply. <i>Mayo Clinic Proceedings</i> , 2003, 78, 118.	3.1	1
621	Response Rate, Durability of Response, and Survival After Thalidomide Therapy for Relapsed Multiple Myeloma. <i>Mayo Clinic Proceedings</i> , 2003, 78, 34-39.	3.1	124
622	Thalidomide in newly diagnosed multiple myeloma and overview of experience in smoldering/indolent disease. <i>Seminars in Hematology</i> , 2003, 40, 17-22.	3.2	12
623	Review of 1027 Patients With Newly Diagnosed Multiple Myeloma. <i>Mayo Clinic Proceedings</i> , 2003, 78, 21-33.	3.1	2,122
624	POEMS syndrome: definitions and long-term outcome. <i>Blood</i> , 2003, 101, 2496-2506.	4.2	747
625	A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma. <i>New England Journal of Medicine</i> , 2003, 348, 2609-2617.	43.7	2,527
626	Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2003, 10, 257-261.	4.7	130
627	Circulating peripheral blood plasma cells as a prognostic indicator in patients with primary systemic amyloidosis. <i>Blood</i> , 2003, 101, 827-830.	4.2	74
628	Prognostic value of angiogenesis in solitary bone plasmacytoma. <i>Blood</i> , 2003, 101, 1715-1717.	4.2	107
629	Long-term follow-up of IgM monoclonal gammopathy of undetermined significance. <i>Blood</i> , 2003, 102, 3759-3764.	4.2	298
630	A Review of Angiogenesis and Anti-Angiogenic Therapy in Hematologic Malignancies. <i>Journal of Hematotherapy and Stem Cell Research</i> , 2002, 11, 33-47.	1.9	35

#	ARTICLE	IF	PR CITATIONS
631	Thrombotic Thrombocytopenic Purpura Associated with a Hepatic Abscess Due to <i>Actinomyces turicensis</i> . <i>Clinical Infectious Diseases</i> , 2002, 35, 636-637.	5.4	25
632	Diagnostic and prognostic value of bone marrow angiogenesis and megakaryocyte c-Mpl expression in essential thrombocythemia. <i>Blood</i> , 2002, 99, 4131-4137.	4.2	60
633	A Long-Term Study of Prognosis in Monoclonal Gammopathy of Undetermined Significance. <i>New England Journal of Medicine</i> , 2002, 346, 564-569.	43.7	1,428
634	Current Therapy for Multiple Myeloma. <i>Mayo Clinic Proceedings</i> , 2002, 77, 813-822.	3.1	101
635	Thalidomide-Induced Neuropathy: In Response. <i>Mayo Clinic Proceedings</i> , 2002, 77, 1395.	3.1	2
636	Genomic abnormalities in monoclonal gammopathy of undetermined significance. <i>Blood</i> , 2002, 100, 1417-1424.	4.2	329
637	Deletions of 17p13.1 and 13q14 are uncommon in Waldenström macroglobulinemia clonal cells and mostly seen at the time of disease progression. <i>Cancer Genetics and Cytogenetics</i> , 2002, 132, 55-60.	1.3	58
638	MONOCLONAL GAMMOPATHIES OF UNDETERMINED SIGNIFICANCE. <i>Reviews in Clinical and Experimental Hematology</i> , 2002, 6, 225-252.	1.7	26
639	Bone marrow angiogenesis in multiple myeloma: effect of therapy. <i>British Journal of Haematology</i> , 2002, 119, 665-671.	2.4	49
640	<i>Helicobacter pylori</i> infection and monoclonal gammopathy of undetermined significance. <i>British Journal of Haematology</i> , 2002, 119, 706-708.	2.4	32
641	Myeloma and the newly diagnosed patient: A focus on treatment and management. <i>Seminars in Oncology</i> , 2002, 29, 5-10.	1.9	87
642	Angiogenesis in multiple myeloma. <i>British Journal of Haematology</i> , 2001, 113, 565-565.	2.4	13
643	Methods for estimation of bone marrow plasma cell involvement in myeloma: Predictive value for response and survival in patients undergoing autologous stem cell transplantation. <i>American Journal of Hematology</i> , 2001, 68, 269-275.	6.1	63
644	Thalidomide in the treatment of multiple myeloma. <i>Expert Review of Anticancer Therapy</i> , 2001, 1, 20-28.	2.6	20
645	Therapeutic application of thalidomide in multiple myeloma. <i>Seminars in Oncology</i> , 2001, 28, 583-587.	1.9	15
646	Angiogenesis in multiple myeloma. <i>Seminars in Oncology</i> , 2001, 28, 560-564.	1.9	5
647	Title is missing!. <i>Journal of Neuro-Oncology</i> , 2000, 49, 255-261.	2.6	11
648	FISH Demonstrates Treatment-Related Chromosome Damage in Myeloid but not Plasma Cells in Primary Systemic Amyloidosis. <i>Leukemia and Lymphoma</i> , 2000, 39, 391-395.	1.5	11

#	ARTICLE	IF	PR CITATIONS
649	Waldenström's Macroglobulinemia. <i>Oncologist</i> , 2000, 5, 63-67.	3.5	110
650	Thalidomide in the Treatment of Relapsed Multiple Myeloma. <i>Mayo Clinic Proceedings</i> , 2000, 75, 897-901.	3.1	174
651	Evaluation and clinical correlations of bone marrow angiogenesis in myelofibrosis with myeloid metaplasia. <i>Blood</i> , 2000, 96, 3374-3380.	4.2	156
652	Plasmablastic Morphology Is an Independent Predictor of Poor Survival After Autologous Stem-Cell Transplantation for Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 1999, 17, 1551-1551.	21.6	66
653	Phase I Evaluation of Preirradiation Chemotherapy with Carmustine and Cisplatin and Accelerated Radiation Therapy in Patients with High-grade Gliomas. <i>Neurosurgery</i> , 1999, 44, 67-73.	1.9	21
654	Clinical Significance of the Translocation (11;14)(q13;q32) in Multiple Myeloma. <i>Leukemia and Lymphoma</i> , 1999, 35, 599-605.	1.5	32
655	PROGNOSTIC FACTORS IN MULTIPLE MYELOMA. <i>Hematology/Oncology Clinics of North America</i> , 1999, 13, 1295-1314.	2.3	99
656	MONOCLONAL GAMMOPATHIES OF UNDETERMINED SIGNIFICANCE. <i>Hematology/Oncology Clinics of North America</i> , 1999, 13, 1181-1202.	2.3	85
657	Screening Mammography in Women Aged 40-49 Years. <i>Medicine (United States)</i> , 1999, 78, 410-416.	1.3	10
658	Phase II North Central Cancer Treatment Group Study of 2-Chlorodeoxyadenosine in Patients With Recurrent Glioma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1999, 22, 168-171.	1.3	11
659	Primary systemic amyloidosis with delayed progression to multiple myeloma. , 1998, 82, 1501-1505.		115
660	Anemia After Orchiectomy. <i>American Journal of Hematology</i> , 1998, 59, 230-233.	6.1	62
661	Diagnostic Value of Albumin Gene Expression in Liver Tumors: Case Report and Review of the Literature. <i>Mayo Clinic Proceedings</i> , 1998, 73, 533-536.	3.1	10
662	Granulomatous Vasculitis Associated With Herpes Virus. <i>Mayo Clinic Proceedings</i> , 1998, 73, 390-391.	3.1	0
663	Combination Chemotherapy with Cisplatin, Carboplatin, and Etoposide in Advanced Malignancy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1997, 20, 500-504.	1.3	3
664	Number needed to treat is a simple measure of treatment efficacy for clinicians. <i>Journal of General Internal Medicine</i> , 1996, 11, 357-359.	2.8	27
665	A classic case of amyloid cardiomyopathy. <i>BMJ Case Reports</i> , 0, , bcr2012006937.	0.4	1
666	Patient Experience in Clinical Trials: Quality of Life, Financial Burden, and Perception of Care in Patients With Multiple Myeloma or Lymphoma Enrolled on Clinical Trials Compared With Standard Care. <i>JCO Oncology Practice</i> , 0, , .	3.0	6